National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (Cth)

National Health (Listing of Pharmaceutical Benefits) Instrument 2012

PB 71 of 2012

made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the

National Health Act 1953

Compilation No. 116

Compilation date: 1 April 2022

Includes amendments up to: F2022L00454

Registered: 14 April 2022

This compilation is in 7 volumes

Volume 1: sections 1–26 and Schedule 1 (Part 1: A–C)

Volume 2: Schedule 1 (Part 1: D–K)

Volume 3: Schedule 1 (Part 1: L–P)

Volume 4: Schedule 1 (Part 1: Q–Z, Part 2), Schedules 2 and 3

Volume 5: Schedule 4 (Part 1: A–E)

Volume 6: Schedule 4 (Part 1: F–R)

Volume 7: Schedule 4 (Part 1: S–Z, Part 3), Schedules 5, 6 and
Endnotes

Each volume has its own contents

About this compilation

This compilation

This is a compilation of the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 that shows the text of the law as amended and in force on 1 April 2022 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register ( The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self‑repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

1............ Name of Instrument....................................................................................................... 1
4............ Definitions..................................................................................................................... 1
5............ Drugs and medicinal preparations to which Part VII applies......................................... 2
6............ Form.............................................................................................................................. 3
7............ Manner of administration.............................................................................................. 3
8............ Brand and responsible person....................................................................................... 3
8A......... Schedule equivalent....................................................................................................... 3
9............ Authorised prescribers—Part 1 of Schedule 1.............................................................. 4
9A......... Authorised prescriber—Schedule 2............................................................................... 4
10.......... Prescription circumstances—Schedule 1....................................................................... 5
10A....... Modified prescription circumstances during COVID‑19 pandemic.............................. 5
11.......... Authority required procedures....................................................................................... 6
12.......... Authority required procedures—submission of prescription......................................... 6
13.......... Authority required procedures—authorisation.............................................................. 7
14.......... Streamlined authority code............................................................................................ 9
15.......... Extended application of sections 11 to 14...................................................................... 9
16.......... Prescription circumstances—Schedule 2....................................................................... 9
17.......... Maximum quantity—Schedule 1................................................................................... 9
18.......... Maximum quantity conditions—Schedule 1................................................................ 10
19.......... Maximum quantity—Schedule 2................................................................................. 10
20.......... Maximum number of repeats—Schedule 1................................................................. 11
21.......... Maximum number of repeats conditions—Schedule 1................................................ 11
22.......... Maximum number of repeats—Schedule 2................................................................. 12
23.......... Determined Quantity................................................................................................... 12
24.......... Pack Quantity.............................................................................................................. 12
25.......... Section 100 only supply.............................................................................................. 13
26.......... Prescriber bag only supply.......................................................................................... 13

Schedule 1—Ready‑prepared pharmaceutical benefits 15

Part 1—Ready‑prepared pharmaceutical benefits for prescription and supply 15

1 Name of Instrument

(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Instrument 2012.

(2) This Instrument may also be cited as PB 71 of 2012.

4 Definitions

In this Instrument:

ABN has the same meaning as in the A New Tax System (Australian Business Number) Act 1999;

Act means the National Health Act 1953;

authorised prescriber, for a pharmaceutical benefit, means a PBS prescriber (within the meaning of Part VII of the Act) authorised under section 9 or 9A to write a prescription for the supply of the benefit;

CFC means chlorofluorocarbon;

CFU means colony forming unit;

circumstances code means the letter ‘C’ followed by a number;

conditions code means the letters ‘CN’ followed by a number;

electronic communication has the meaning given by subsection 5(1) of the Electronic Transactions Act 1999;

electronic prescription has the meaning given by the Regulations;

extemporaneously‑prepared pharmaceutical benefit means a pharmaceutical benefit other than a ready‑prepared pharmaceutical benefit;

General Statement for drugs for the treatment of hepatitis C means the statement set out in Part 3 of Schedule 4;

GP Management Plan means a comprehensive written plan for the treatment of a patient, prepared by a medical practitioner, that includes a description of the patient’s health care needs, management goals, actions to be taken by the patient and treatment and services the patient is likely to need;

I.M. means intramuscular;

I.U. means international unit;

I.V. means intravenous;

Medicare Benefits Schedule means the Health Insurance (General Medical Services Table) Regulations;

mmol means millimole;

palliative care patient means a patient with an active, progressive, far‑advanced disease for whom the prognosis is limited and the focus of care is the quality of life;

paper‑based prescription has the meaning given by the Regulations;

PBS means Pharmaceutical Benefits Scheme;

purposes code means the letter ‘P’ followed by a number;

ready‑prepared pharmaceutical benefit means a brand of a pharmaceutical item in relation to which a determination under subsection 85(6) of the Act is in force;

Regulations means the National Health (Pharmaceutical Benefits) Regulations 2017;

residential care service has the meaning given by the Regulations;

Streamlined Authority Code means the words ‘Streamlined Authority Code’ followed by a number;

Team Care Arrangements means a document prepared by a medical practitioner, following consultation with collaborating providers, that includes a description of the treatment and service goals for the patient, the treatment and services that all collaborating providers will provide and the actions to be taken by the patient;

TGA means Therapeutic Goods Administration;

WHO means World Health Organisation.

Note: Terms used in this Instrument have the same meaning as in the Act—see section 13 of the Legislative Instruments Act 2003. These terms include:

· Chief Executive Medicare

· pharmaceutical benefit

· pharmaceutical item.

Drugs and medicinal preparations to which Part VII applies

(1) For paragraph 85(2)(a) of the Act, Part VII of the Act applies to:

(a) a drug or medicinal preparation mentioned in the column headed ‘Listed Drug’ in:

(i) Schedule 1; or

(ii) Part 1 of Schedule 2; and

(b) a medicinal preparation composed of 1 or more listed drugs mentioned in subparagraph (a)(ii).

(2) For subparagraph 85(2)(b)(i) of the Act, paragraph 85(2)(b) of the Act applies to a listed drug mentioned in subparagraph (1)(a)(ii).

(3) For subparagraph 85(2)(b)(ii) of the Act, paragraph 85(2)(b) of the Act applies to an additive mentioned in Part 2 of Schedule 2.

Note: Part VII of the Act applies to medicinal preparations composed of 1 or more listed drugs mentioned in subsection (2) and 1 or more of the additives mentioned in subsection (3)—see paragraph 85(2)(b) of the Act.

6 Form

For subsection 85(3) of the Act, the column headed ‘Form’ in Schedule 1 lists the form or forms for a listed drug determined for that drug.

7 Manner of administration

(1) For subsection 85(5) of the Act, the manner of administration of a form of a listed drug mentioned in Schedule 1 is the manner of administration mentioned for that form of the drug in the column headed ‘Manner of Administration’ in Schedule 1.

(2) For paragraph 85A(2)(c) of the Act, if a manner of administration is mentioned in Schedule 1 for a form of a listed drug, a person writing a prescription for the supply of a pharmaceutical benefit that has the listed drug in that form must, if including a manner of administration in the prescription, direct that the pharmaceutical benefit be administered in that manner.

(3) For subsection (2), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

8 Brand and responsible person

(1) A brand mentioned in the column headed ‘Brand’ in Schedule 1 for a pharmaceutical item is determined for subsection 85(6) of the Act for that pharmaceutical item.

(2) For subsection 84AF(1) of the Act, if a code is mentioned in the column in Schedule 1 headed ‘Responsible Person’ for a brand of a pharmaceutical item, the person mentioned in subsection (3) is the responsible person for the brand of the pharmaceutical item.

(3) For subsection (2), the person is the person mentioned in Schedule 3 for the code, with the ABN, if any, mentioned in Schedule 3 for the person.

(4) For subsections (1) and (2), the pharmaceutical item is the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

8A Schedule equivalent

(1) For subsection 85(6A) of the Act:

(a) a brand of a pharmaceutical item with an ‘a’ located in the column headed ‘Schedule Equivalent’ in Schedule 1, is to be treated as equivalent to another brand of that pharmaceutical item that also has an ‘a’ located in the column headed ‘Schedule Equivalent’ in Schedule 1;

(b) where paragraph (a) applies to a brand of a pharmaceutical item, a brand of the same pharmaceutical item with a ‘b’ in the column headed ‘Schedule equivalent’ in Schedule 1, is to be treated as equivalent to another brand of that pharmaceutical item that also has a ‘b’ located in the column headed ‘Schedule Equivalent’ in Schedule 1; and

(c) where a brand of a pharmaceutical item appears in Schedule 5, that brand is to be treated as equivalent to any brand of any pharmaceutical item that is in the same schedule equivalent group as that brand in Schedule 5.

Authorised prescribers—Part 1 of Schedule 1

(1A) For subsection 88(1) of the Act, a medical practitioner is authorised to write a prescription for the supply of any pharmaceutical benefit mentioned in Part 1 of Schedule 1.

(1) For subsection 88(1A) of the Act, a participating dental practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials PDP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Part 1 of Schedule 1.

(2) For subsection 88(1C) of the Act, an authorised optometrist is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials AO are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Part 1 of Schedule 1.

(3) For subsection 88(1D) of the Act, an authorised midwife is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials MW are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Part 1 of Schedule 1.

(4) For subsection 88(1E) of the Act, an authorised nurse practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials NP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Part 1 of Schedule 1.

(5) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Part 1 of Schedule 1:

(a) in the form mentioned in Part 1 of Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Part 1 of Schedule 1 for the form of the listed drug.

9A Authorised prescriber—Schedule 2

For the purposes of subsection 88(1) of the Act, a medical practitioner is authorised to write a prescription for the supply of an extemporaneously‑prepared pharmaceutical benefit.

Prescription circumstances—Schedule 1

(1) This section applies to a pharmaceutical benefit if at least 1 circumstances code is mentioned in the column in Schedule 1 headed ‘Circumstances’ for the pharmaceutical benefit.

(2) For paragraph 85(7)(a) of the Act, the pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.

(3) For paragraph 85(7)(b) of the Act, the circumstances in which a prescription for the supply of the pharmaceutical benefit may be written are the circumstances mentioned in Part 1 of Schedule 4 for at least 1 of the circumstances codes mentioned in Schedule 1 for the pharmaceutical benefit.

(3A) Subsection (3) has effect subject to section 10A (which temporarily modifies the circumstances mentioned in Part 1 of Schedule 4 for circumstances codes for pharmaceutical benefits that are pharmaceutical items described in Schedule 6).

(4) For subsection (1), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

10A Modified prescription circumstances during COVID‑19 pandemic

(1) This section affects the circumstances in which a prescription may be written by an authorised prescriber for the supply of a pharmaceutical benefit that is a listed brand of a pharmaceutical item described in Schedule 6 to a person (the patient) if the authorised prescriber is satisfied the patient has, in accordance with Part VII of the Act, already been supplied with the benefit on the basis of a prescription written in circumstances determined by subsection 10(3) unaffected by this section.

(2) For the purposes of subsection 10(3), Part 1 of Schedule 4 has effect as if each circumstances code for the pharmaceutical benefit:

(a) did not mention any circumstance that, having regard to the patient’s situation and the state of affairs associated with precautions against the spread of the coronavirus known as COVID‑19, it is not reasonably practicable to establish in relation to the patient; and

(b) mentioned the circumstance that the authorised prescriber keeps a written record of the reason it is not practicable to establish the circumstance described in paragraph (a).

(3) This section, subsection 10(3A) and Schedule 6 are repealed at the start of 1 July 2022.

11 Authority required procedures

(1) This section applies to a pharmaceutical benefit if the circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit include any of the following:

(a) Compliance with Authority Required procedures;

(b) Compliance with Written Authority Required procedures;

(c) Compliance with Telephone Authority Required procedures;

(d) Compliance with Written or Telephone Authority Required procedures.

(1A) If the circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit include the words ‘Compliance with Telephone Authority Required procedures’ or ‘Compliance with Written or Telephone Authority Required procedures’ treat as if the words used are ‘Compliance with Authority Required procedures’.

Note: If there is a Streamlined Authority Code section 14 continues to apply.

(2) A prescription for the supply of the pharmaceutical benefit must be:

(a) submitted by the authorised prescriber to the Chief Executive Medicare in accordance with section 12; and

(b) authorised by the Chief Executive Medicare in accordance with section 13.

12 Authority required procedures—submission of prescription

(1) A prescription is submitted in accordance with this subsection if:

(a) the authorised prescriber submits to the Chief Executive Medicare:

(i) the prescription itself; or

(ii) for a medication chart prescription that is not an electronic prescription — the medication chart by which the prescription was written, or a copy of so much of that chart as would indicate that subsection 41(2) of the Regulations has been complied with; or

(b) the authorised prescriber submits details of the prescription by telephone to the Chief Executive Medicare; or

(c) the authorised prescriber submits the prescription in accordance with the instructions in an emergency telephone message provided to the authorised prescriber by the Chief Executive Medicare; or

(d) the authorised prescriber submits details of the prescription in accordance with subsection 12(4A) to the Chief Executive Medicare, by means of electronic communication to obtain an electronic authority.

(2) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(a) or (d).

(3) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(b) or (c).

(4) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written or Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(a), (b) or (c).

(4A) The prescription submitted in accordance with paragraph 12(1)(d) must be:

(a) given to the Chief Executive Medicare in writing; and

(b) by means of an electronic communication; and

(c) encrypted when it is given to the Chief Executive Medicare; and

(d) in accordance with any other requirements that would need to be met in order for the requirements to give the information in writing to be taken to have been met under the Electronic Transactions Act 1999.

(5) For paragraph (1)(a), a prescription prepared and signed by the authorised prescriber in accordance with subsection (1) is taken to have been submitted by the authorised prescriber if it is submitted by his or her employee.

13 Authority required procedures—authorisation

(1) A paper‑based prescription (other than a prescription submitted in accordance with paragraph 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare signing his or her authorisation on the prescription, and:

(a) if the Chief Executive Medicare requires the authorised prescriber to alter the prescription — returning it to the authorised prescriber for alteration before the authorised prescriber gives it to the person in respect of whom it was prepared; or

(b) by returning it to the authorised prescriber; or

(c) if requested by the authorised prescriber — sending it to the person in respect of whom it was prepared.

(1A) A medication chart prescription (other than an electronic prescription, or a prescription submitted in accordance with paragraphs 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare signing his or her authorisation on the medication chart prescription, or a copy of the medication chart prescription, and:

(a) if the Chief Executive Medicare requires the authorised prescriber to alter the prescription— indicating this on the medication chart prescription or copy; and

(b) returning the medication chart or copy to the authorised prescriber for alteration.

(1B) An electronic prescription (other than a prescription submitted in accordance with paragraphs 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare writing his or her authorisation on the electronic prescription, and:

(a) if the Chief Executive Medicare requires the authorised prescriber to alter the prescription— by returning it, including by means of an electronic communication, to the authorised prescriber for alteration; or

(b) by returning it, including by means of electronic communication to the authorised prescriber; or

(c) if requested by the authorised prescriber — sending it to the person in respect of whom it was prepared.

(2) A prescription submitted in accordance with paragraph 12(1)(b) may be authorised by the Chief Executive Medicare telling the authorised prescriber by telephone, at the time the Chief Executive Medicare is given details of the prescription, that the prescription is authorised.

(3) A prescription submitted in accordance with paragraph 12(1)(d) may be authorised by the Chief Executive Medicare sending his or her authorisation, by electronic communication, including computer automated electronic communication, to the authorised prescriber.

(3A) If the prescription submitted is declined for authorisation, the authorised prescriber may seek review of the decision by the Chief Executive Medicare.

(4) If the Chief Executive Medicare authorises a prescription under subsection (2) or (3):

(a) the Chief Executive Medicare must tell the authorised prescriber the number that has been allotted to the authorised prescription: and

(b) the authorised prescriber must:

(i) mark that number on the prescription; and

(ii) retain a copy of the prescription showing the number marked in accordance with subparagraph (i) for 1 year from the date the prescription was authorised.

(5) For paragraph (4)(a), the Chief Executive Medicare must tell the authorised prescriber the number:

(i) if the authorised prescriber is an authorised optometrist—by telephone; and

(ii) in any other case—by telephone or by electronic communication.

(6) A prescription submitted in accordance with paragraph 12(1)(c) is taken to have been authorised by the Chief Executive Medicare if the authorised prescriber completes the prescription in accordance with the instructions given in the emergency telephone message.

14 Streamlined authority code

(1) This section applies to a pharmaceutical benefit if the circumstances mentioned in Schedule 4 for a circumstances code applying to the pharmaceutical benefit include a Streamlined Authority Code.

(2) The requirements of section 12 are taken to have been complied with, and the Chief Executive Medicare is taken to have authorised the prescription of the pharmaceutical benefit under section 13, if the authorised prescriber has written the Streamlined Authority Code on the prescription.

Extended application of sections 11 to 14

Sections 11 to 14 apply in relation to conditions and conditions codes as if the circumstances and circumstances codes mentioned in those sections were conditions and conditions codes.

Note: Conditions are determined in sections 18 and 21.

Prescription circumstances—Schedule 2

(1) For paragraph 85(7)(a) of the Act, a pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A if:

(a) it is:

(i) a listed drug mentioned in Part 1 of Schedule 2; or

(ii) an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug; and

(b) there are circumstances mentioned for the listed drug in the column headed ‘Circumstances’ in Part 1 of Schedule 2.

(2) For paragraph 85(7)(b) of the Act, the circumstances in which a prescription for the supply of a pharmaceutical benefit mentioned in subsection (1) may be written are:

(a) for a listed drug mentioned in subparagraph (1)(a)(i)—the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for the drug; and

(b) for an extemporaneously‑prepared pharmaceutical benefit mentioned in subparagraph (1)(a)(ii)—the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for each listed drug contained in the pharmaceutical benefit.

Note: If an extemporaneously‑prepared pharmaceutical benefit contains more than one listed drug, a prescription for the supply of the pharmaceutical benefit may only be written if the circumstances mentioned for each of the listed drugs contained in the pharmaceutical benefit are met.

Maximum quantity—Schedule 1

(1) For paragraph 85A(2)(a) of the Act, the maximum quantity or number of units of the pharmaceutical item in a pharmaceutical benefit mentioned in Schedule 1 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for the pharmaceutical benefit and authorised prescriber.

(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for a pharmaceutical benefit, the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.

(3) If no purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’, the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.

(4) For subsection (1) the pharmaceutical item is the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(5) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Maximum quantity conditions—Schedule 1

(1) This section applies to a pharmaceutical benefit if a conditions code is mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for a maximum quantity or number of units for the pharmaceutical benefit.

(2) For subsection 85A(2A) of the Act, the conditions which must be satisfied when writing a prescription for the supply of the pharmaceutical benefit to which a determination of a maximum quantity or number of units under paragraph 85A(2)(a) applies, are the conditions mentioned in Part 1 of Schedule 4 for the conditions code mentioned in Schedule 1 for the pharmaceutical benefit and the maximum quantity or number of units.

(3) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Maximum quantity—Schedule 2

(1) For paragraph 85A(2)(a) of the Act, the maximum quantity or number of units of an extemporaneously‑prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.

(2) For subsection (1), the extemporaneously‑prepared pharmaceutical benefit is:

(a) the listed drug mentioned in Part 1 of Schedule 2; or

(b) an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug.

Maximum number of repeats—Schedule 1

(1) For paragraph 85A(2)(b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of a pharmaceutical benefit mentioned in Schedule 1 be repeated is the number in the column in Schedule 1 headed ‘Number of Repeats’ for the pharmaceutical benefit and the authorised prescriber.

(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for the pharmaceutical benefit, the number of repeats mentioned in the column in Schedule 1 headed ‘Number of Repeats’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.

(3) If no purposes code is mentioned in the column headed ‘Purposes’, the number of repeats mentioned in the column headed ‘Number of Repeats’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.

(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Maximum number of repeats conditions—Schedule 1

(1) This section applies to a pharmaceutical benefit if a conditions code is mentioned in the column in Schedule 1 headed ‘Number of Repeats’ for the maximum number of repeats for the pharmaceutical benefit.

(2) For subsection 85A(2A) of the Act, the conditions which must be satisfied when writing a prescription for the supply of the pharmaceutical benefit to which a determination of a maximum number of repeats under paragraph 85A(2)(b) applies, are the conditions mentioned in Part 1 of Schedule 4 for the conditions code mentioned in Schedule 1 for the pharmaceutical benefit and the maximum number of repeats.

(3) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Maximum number of repeats—Schedule 2

(1) For paragraph 85A(2)(b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of an extemporaneously‑prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 be repeated is the number in the column headed ‘Number of Repeats’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.

(2) For this section, the extemporaneously‑prepared pharmaceutical benefit is:

(a) the listed drug mentioned in Part 1 of Schedule 2; or

(b) an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug.

23 Determined Quantity

(1) For subsection 84AK(3) of the Act, the quantities or numbers of units of a pharmaceutical item that are determined quantities of a listed brand of the pharmaceutical item mentioned in Schedule 1 are the quantities or numbers of units mentioned in the column in Schedule 1 headed ‘Determined Quantity’ for the listed brand of the pharmaceutical item.

(2) For this section, the listed brand of the pharmaceutical item is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(3) For this section, the pharmaceutical item is the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

24 Pack Quantity

(1) For subsection 84AK(2) of the Act, the quantities or numbers of units of a pharmaceutical item that are pack quantities of a listed brand of the pharmaceutical item mentioned in Schedule 1 are the quantities or numbers of units mentioned in the column in Schedule 1 headed ‘Pack Quantity’ for the listed brand of the pharmaceutical item.

(2) For this section, the listed brand of the pharmaceutical item is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(3) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Section 100 only supply

(1) For subsection 85(2A) of the Act, if the code D(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a listed drug, the drug can only be supplied under special arrangements under section 100 of the Act.

(2) For paragraph 85(8)(a) of the Act, if the code PB(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, the pharmaceutical benefit can only be supplied under special arrangements under section 100 of the Act.

(3) For paragraph 85(8)(b) of the Act, if the code C(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, and a circumstances code is mentioned for the pharmaceutical benefit in the column headed ‘Circumstances’, the pharmaceutical benefit can be supplied in the circumstances identified in Part 1 of Schedule 4 for the circumstances code only under special arrangements under section 100 of the Act.

(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

26 Prescriber bag only supply

(1) For subsection 85(2AA) of the Act, if one or more of the codes D(MP), D(MW) and D(NP) are mentioned in the column headed ‘Section 100/ Prescriber Bag only’ in Schedule 1 for a listed drug other than the drug methoxyflurane, then, subject to subsection (3), the drug can only be supplied by:

(a) where the code D(MP) is mentioned, medical practitioners under section 93 of the Act, and

(b) where the code D(MW) is mentioned, authorised midwives under section 93AA of the Act, and

(c) where the code D(NP) is mentioned, authorised nurse practitioners under section 93AB of the Act.

Note: A declaration in force immediately before 1 October 2012 for the purposes of subsection 85(2A) of the Act declaring that the drug methoxyflurane can only be supplied under special arrangements under section 100 of the Act, continues in force and may be dealt with on and after 1 October 2012, as if the declaration had been made for the purposes of subsection 85(2AA) of the Act and declared that methoxyflurane can only be supplied under section 93 of the Act (see Item 18 of Schedule 3 to the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2012).

(2) For subsection 85(7A) of the Act, if one or more of the codes PB(MP), PB(MW) and PB(NP) are mentioned in the column headed ‘Section 100/ Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, then, subject to subsection (3), the pharmaceutical benefit can only be supplied by:

(a) where the code PB(MP) is mentioned, medical practitioners under section 93 of the Act, and

(b) where the code PB(MW) is mentioned, authorised midwives under section 93AA of the Act, and

(c) where the code PB(NP) is mentioned, authorised nurse practitioners under section 93AB of the Act.

(3) If :

(a) one or more of the codes D(MP), D(MW), and D(NP) are mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a listed drug; and

(b) one or more of the codes PB(MP), PB(MW) and PB(NP) are also mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit having the listed drug;

then:

(c) the drug may be supplied as provided in subsection (1): and

(d) the pharmaceutical benefit may be supplied as provided in subsection (2).

(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Schedule 1—Ready‑prepared pharmaceutical benefits

Note: See sections 5 to 10, 16 to 18, 20, 21 and 23 to 26.

Part 1—Ready‑prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes			Maximum Quantity		Number of Repeats		Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Abacavir	Oral solution 20 mg (as sulfate) per mL, 240 mL	Oral	Ziagen	VI	MP NP	C4454 C4512	8	5		1	D(100)
Abacavir	Tablet 300 mg (as sulfate)	Oral	Ziagen	VI	MP NP	C4454 C4512	120	5		60	D(100)
Abacavir with lamivudine	Tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg	Oral	Abacavir/Lamivudine GH 600/300	GQ	MP NP	C4527 C4528	60	5		30	D(100)
	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	Oral	ABACAVIR/LAMIVUDINE 600/300 SUN	RA	MP NP	C4527 C4528	60	5		30	D(100)
			Abacavir/Lamivudine Mylan	AF	MP NP	C4527 C4528	60	5		30	D(100)
			Kivexa	VI	MP NP	C4527 C4528	60	5		30	D(100)
Abacavir with lamivudine and zidovudine	Tablet containing abacavir 300 mg (as sulfate) with lamivudine 150 mg and zidovudine 300 mg	Oral	Trizivir	VI	MP NP	C4480 C4495	120	5		60	D(100)
Abatacept	Injection 125 mg in 1 mL single dose autoinjector	Injection	Orencia ClickJect	BQ	MP	C8627 C8638 C8655 C8746 C11776 C11805 C12378 C12385	P8638 P8746 P11776 P11805				4	3		4
	Injection 125 mg in 1 mL single dose autoinjector	Injection	Orencia ClickJect	BQ	MP	C8627 C8638 C8655 C8746 C11776 C11805 C12378 C12385	P8627 P8655 P12378 P12385				4	5		4
	Injection 125 mg in 1 mL single dose pre‑filled syringe	Injection	Orencia	BQ	MP	C8627 C8638 C8655 C8746 C11776 C11805 C12378 C12385	P8638 P8746 P11776 P11805				4	3		4
	Injection 125 mg in 1 mL single dose pre‑filled syringe	Injection	Orencia	BQ	MP	C8627 C8638 C8655 C8746 C11776 C11805 C12378 C12385	P8627 P8655 P12378 P12385				4	5		4
	Powder for I.V. infusion 250 mg	Injection	Orencia	BQ	MP	See Note 3	See Note 3				See Note 3	See Note 3		1	PB(100)
Abemaciclib	Tablet 50 mg	Oral	Verzenio	LY	MP	C12348 C12367 C12380	56	5		56
Tablet 100 mg	Oral	Verzenio	LY	MP	C12348 C12367 C12380	56	5		56
Tablet 150 mg	Oral	Verzenio	LY	MP	C12348 C12367 C12380	56	5		56
Abiraterone	Tablet containing abiraterone acetate 250 mg	Oral	Zytiga	JC	MP	C12352	120	2		120
Abiraterone	Tablet containing abiraterone acetate 500 mg	Oral	Zytiga	JC	MP	C12352	60	2		60
Acalabrutinib	Capsule 100 mg	Oral	Calquence	AP	MP	C10652 C12481 C12495 C12500 C12501	56	5		56
Acamprosate	Tablet (enteric coated) containing acamprosate calcium 333 mg	Oral	a	Acamprosate Mylan	AL	MP NP	C5366	180	1		180
			a	APO‑Acamprosate	TX	MP NP	C5366	180	1		180
			a	Campral	AF	MP NP	C5366	180	1		180
Acarbose	Tablet 50 mg	Oral	a	Acarbose Mylan	AF	MP NP	90	5		90
	a	GLYBOSAY	RW	MP NP	90	5		90
	Tablet 100 mg	Oral	a	Acarbose Mylan	AF	MP NP	90	5		90
a	GLYBOSAY	RW	MP NP	90	5		90
Acetazolamide	Tablet 250 mg	Oral	Diamox	RW	MP NP	100	3		100
Aciclovir	Eye ointment 30 mg per g, 4.5 g	Application to the eye	a	ViruPOS	AE	MP NP	C5965	1	0		1
	AO	C5964	1	0		1
	a	XOROX	IX	MP NP	C5965	1	0		1
	AO	C5964	1	0		1
	Tablet 200 mg	Oral	a	Aciclovir APOTEX	TY	MP NP	C5936 C5942	P5936				50	0		50
			a	Aciclovir Sandoz	HX	MP NP	C5936 C5942	P5936				50	0		25
			a	APO‑Aciclovir	TX	MP NP	C5936 C5942	P5936				50	0		50
			a	GenRx Aciclovir	GX	MP NP	C5936 C5942	P5936				50	0		50
			a	Aciclovir APOTEX	TY	MP NP	C5936 C5942	P5942				90	5		90
			a	Aciclovir GH	GQ	MP NP	C5942	90	5		90
			a	Aciclovir Sandoz	HX	MP NP	C5936 C5942	P5942				90	5		90
			a	APO‑Aciclovir	TX	MP NP	C5936 C5942	P5942				90	5		90
			a	GenRx Aciclovir	GX	MP NP	C5936 C5942	P5942				90	5		90
	Tablet 800 mg	Oral	a	Aciclovir APOTEX	TY	MP NP	C5959 C5967	35	0		35
			a	Aciclovir Sandoz	HX	MP NP	C5959 C5967	35	0		35
			a	APO‑Aciclovir	TX	MP NP	C5959 C5967	35	0		35
			a	GenRx Aciclovir	GX	MP NP	C5959 C5967	35	0		35
Acitretin	Capsule 10 mg	Oral	a	Neotigason	TB	MP	C5727 C5789	100	2		100
	Capsule 10 mg	Oral	a	ZETIN	RW	MP	C5727 C5789	100	2		100
	Capsule 25 mg	Oral	a	Neotigason	TB	MP	C5727 C5789	100	2		100
	Capsule 25 mg	Oral	a	ZETIN	RW	MP	C5727 C5789	100	2		100
Aclidinium	Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses	Inhalation by mouth	Bretaris Genuair	FK	MP NP	C4516	1	5		1
Aclidinium with formoterol	Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses	Inhalation by mouth	Brimica Genuair	FK	MP NP	C7798	1	5		1
Adalimumab	Injection 20 mg in 0.2 mL pre‑filled syringe	Injection	Humira	VE	MP	See Note 3	See Note 3				See Note 3	See Note 3	2		C(100)
MP	C9715 C11713 C11715 C11716 C11717 C11761 C11767 C11852 C11853 C11854 C11855 C11903 C11966	P11713				2	0	2
MP	C9715 C11713 C11715 C11716 C11717 C11761 C11767 C11852 C11853 C11854 C11855 C11903 C11966	P9715 P11715 P11716 P11761 P11852 P11854 P11855				2	3	2
MP	C9715 C11713 C11715 C11716 C11717 C11761 C11767 C11852 C11853 C11854 C11855 C11903 C11966	P11717 P11767 P11853 P11903 P11966				2	5	2
Injection 20 mg in 0.4 mL pre‑filled syringe	Injection	Amgevita	TX	MP	See Note 3	See Note 3				See Note 3	See Note 3	1		C(100)
MP	C9715 C11579 C11713 C11715 C11716 C11717 C11718 C11761 C11767 C11852 C11853 C11854 C11855 C11903 C11966	P11713				2	0	1
MP	C9715 C11579 C11713 C11715 C11716 C11717 C11718 C11761 C11767 C11852 C11853 C11854 C11855 C11903 C11966	P9715 P11715 P11716 P11761 P11852 P11854 P11855				2	3	1
MP	C9715 C11579 C11713 C11715 C11716 C11717 C11718 C11761 C11767 C11852 C11853 C11854 C11855 C11903 C11966	P11579 P11717 P11718 P11767 P11853 P11903 P11966				2	5	1
MP	C11526 C12116	2	5	1		C(100)
Injection 40 mg in 0.4 mL pre‑filled pen	Injection	Humira	VE	MP	See Note 3	See Note 3				See Note 3	See Note 3	2		C(100)
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P11713				2	0	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147				2	2	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199				2	3	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P11107 P12103 P12105 P12153 P12155 P12161 P12212				2	4	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P11704 P11711 P11717 P11720 P11767 P11769 P11772 P11853 P11865 P11867 P11903 P11906 P11966 P12122 P12123 P12148 P12156 P12157 P12158 P12175 P12176 P12189 P12190 P12214 P12228 P12234 P12240 P12354 P12364 P12366 P12391				2	5	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P12273				4	2	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P12272 P12315				4	5	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P12275 P12336				6	0	2
Injection 40 mg in 0.4 mL pre‑filled syringe	Injection	Humira	VE	MP	See Note 3	See Note 3				See Note 3	See Note 3	2		C(100)
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12354 C12364 C12366 C12391	P11713				2	0	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12354 C12364 C12366 C12391	P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147				2	2	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12354 C12364 C12366 C12391	P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199				2	3	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12354 C12364 C12366 C12391	P11107 P12103 P12105 P12153 P12155 P12161 P12212				2	4	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12354 C12364 C12366 C12391	P11704 P11711 P11717 P11720 P11767 P11769 P11772 P11853 P11865 P11867 P11903 P11906 P11966 P12122 P12123 P12148 P12156 P12157 P12158 P12175 P12176 P12189 P12190 P12214 P12228 P12234 P12240 P12354 P12364 P12366 P12391				2	5	2
MP	C8638 C9064 C9386 C9715 C11107 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12354 C12364 C12366 C12391	P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147				6	0	2
Injection 40 mg in 0.8 mL pre‑filled pen	Injection	Amgevita	TX	MP	See Note 3	See Note 3				See Note 3	See Note 3	2		C(100)
Hadlima	RF	MP	See Note 3	See Note 3				See Note 3	See Note 3	2		C(100)
Hyrimoz	SZ	MP	See Note 3	See Note 3				See Note 3	See Note 3	2		C(100)
Idacio	PK	MP	See Note 3	See Note 3				See Note 3	See Note 3	2		C(100)
Amgevita	TX	MP	C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P11713				2	0	2
Hadlima	RF	MP	C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P11713				2	0	2
Hyrimoz	SZ	MP	C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P11713				2	0	2
Idacio	PK	MP	C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P11713				2	0	2
Amgevita	TX	MP	C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147				2	2	2
Hadlima	RF	MP	C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147				2	2	2
Hyrimoz	SZ	MP	C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391	P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147				2	2	2

Idacio

C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11529 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12272 C12273 C12275 C12315 C12336 C12354 C12364 C12366 C12391

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Amgevita

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Hadlima

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Hyrimoz

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Idacio

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Amgevita

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Hadlima

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Hyrimoz

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Idacio

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Amgevita

P11523 P11524 P11579 P11604 P11605 P11606 P11631 P11634 P11635 P11704 P11711 P11717 P11718 P11720 P11767 P11769 P11772 P11853 P11865 P11867 P11903 P11906 P11966 P12122 P12123 P12148 P12156 P12157 P12158 P12175 P12176 P12189 P12190 P12214 P12228 P12234 P12240 P12354 P12364 P12366 P12391

C11526 C12116

C(100)

Hadlima

C11526 C12116

C(100)

Hyrimoz

C11526 C12116

C(100)

Idacio

C11526 C12116

C(100)

Amgevita

P12273

Hadlima

P12273

Hyrimoz

P12273

Idacio

P12273

Amgevita

P11529 P12272 P12315

Hadlima

P11529 P12272 P12315

Hyrimoz

P11529 P12272 P12315

Idacio

P11529 P12272 P12315

Amgevita

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P12275 P12336

Hadlima

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P12275 P12336

Hyrimoz

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P12275 P12336

Idacio

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P12275 P12336

Injection 40 mg in 0.8 mL pre‑filled syringe

Injection

Amgevita

See Note 3

C(100)

Hadlima

See Note 3

C(100)

Hyrimoz

See Note 3

C(100)

Idacio

See Note 3

C(100)

Amgevita

C8638 C9064 C9386 C9715 C11107 C11523 C11524 C11579 C11604 C11605 C11606 C11631 C11634 C11635 C11704 C11706 C11707 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11720 C11722 C11759 C11761 C11767 C11769 C11771 C11772 C11810 C11852 C11853 C11854 C11855 C11861 C11865 C11866 C11867 C11903 C11906 C11966 C11972 C12098 C12101 C12103 C12105 C12118 C12122 C12123 C12130 C12131 C12147 C12148 C12153 C12155 C12156 C12157 C12158 C12161 C12171 C12174 C12175 C12176 C12189 C12190 C12194 C12199 C12212 C12214 C12228 C12234 C12240 C12354 C12364 C12366 C12391

P11713

Hadlima

P11713

Hyrimoz

P11713

Idacio

P11713

Amgevita

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Hadlima

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Hyrimoz

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Idacio

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Amgevita

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Hadlima

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Hyrimoz

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Idacio

P8638 P9064 P9386 P11722 P11771 P11810 P11861 P11866 P11972 P12118 P12130 P12131 P12171 P12174 P12194 P12199

Amgevita

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Hadlima

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Hyrimoz

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Idacio

P11107 P12103 P12105 P12153 P12155 P12161 P12212

Amgevita

C11526 C12116

C(100)

Hadlima

C11526 C12116

C(100)

Hyrimoz

C11526 C12116

C(100)

Idacio

C11526 C12116

C(100)

Amgevita

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Hadlima

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Hyrimoz

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Idacio

P9715 P11706 P11707 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147

Injection 80 mg in 0.8 mL pre‑filled pen

Injection

Humira

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P12103 P12105 P12153 P12155 P12161 P12212

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P12273

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P12306

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P11758 P11759 P11761 P11762 P11763 P11789 P11852 P11854 P11855 P12152 P12229 P12275 P12278

Injection 80 mg in 0.8 mL pre‑filled syringe

Injection

Humira

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P12103 P12105 P12153 P12155 P12161 P12212

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P12273

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P12306

C11758 C11759 C11761 C11762 C11763 C11789 C11852 C11854 C11855 C12103 C12105 C12152 C12153 C12155 C12161 C12212 C12229 C12273 C12275 C12278 C12306

P11758 P11759 P11761 P11762 P11763 P11789 P11852 P11854 P11855 P12152 P12229 P12275 P12278

Adapalene with benzoyl peroxide

Gel 1 mg‑25 mg per g, 30 g

Application

Epiduo

C4898 C4961

P4961

C4898 C4961

P4898

C4898

Adefovir

Tablet containing adefovir dipivoxil 10 mg

Oral

APO‑Adefovir

MP NP

C4490 C4510

D(100)

Adrenaline (epinephrine)

I.M. injection 150 micrograms in 0.3 mL single dose syringe auto‑injector

Injection

Adrenaline Jr Mylan

MP NP

C4909 C4947 C8734

Anapen Junior 150

MP NP

C4909 C4947 C8734

EpiPen Jr.

MP NP

C4909 C4947 C8734

I.M. injection 300 micrograms in 0.3 mL single dose syringe auto‑injector

Injection

Adrenaline Mylan

MP NP

C4909 C4947 C8734

Anapen 300

MP NP

C4909 C4947 C8734

EpiPen

MP NP

C4909 C4947 C8734

I.M. injection 500 micrograms in 0.3 mL single dose syringe auto‑injector

Injection

Anapen 500

MP NP

C4909 C4947 C8734

Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000)

Injection

Link Medical Products Pty Ltd

PDP MP NP

MP NP

Afatinib

Tablet 20 mg

Oral

Giotrif

C4473 C7613

Tablet 30 mg

Oral

Giotrif

C4473 C7613

Tablet 40 mg

Oral

Giotrif

C4473 C7613

Tablet 50 mg

Oral

Giotrif

C4473 C7613

Aflibercept

Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre‑filled syringe

Injection

Eylea

C10708 C10715 C10716 C10783 C10789 C10818 C10826 C10827 C10862 C10911

P10708 P10715 P10783 P10789 P10818 P10827 P10862 P10911

C10708 C10715 C10716 C10783 C10789 C10818 C10826 C10827 C10862 C10911

P10716 P10826

Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)

Injection

Eylea

C10708 C10715 C10716 C10783 C10789 C10818 C10826 C10827 C10862 C10911

P10708 P10715 P10783 P10789 P10818 P10827 P10862 P10911

C10708 C10715 C10716 C10783 C10789 C10818 C10826 C10827 C10862 C10911

P10716 P10826

Albendazole

Tablet 200 mg

Oral

Zentel

MP NP

C5680 C5712 C5797 C5817

P5712 P5797 P5817

MP NP

C5680 C5712 C5797 C5817

P5680

Tablet 400 mg

Oral

Eskazole

C5607

Alectinib

Capsule 150 mg

Oral

Alecensa

C7345 C7346

224

Alemtuzumab

Solution concentrate for I.V. infusion 12 mg in 1.2 mL

Injection

Lemtrada

C6847 C7714 C9589 C9636

P6847 P9589

D(100)

C6847 C7714 C9589 C9636

P7714 P9636

D(100)

Alendronic acid

Tablet 70 mg (as alendronate sodium)

Oral

Alendro Once Weekly

MP NP

C6310 C6323 C6327

Alendronate Sandoz

MP NP

C6310 C6323 C6327

APO‑Alendronate

MP NP

C6310 C6323 C6327

Fonat

MP NP

C6310 C6323 C6327

Alendronic acid with colecalciferol

Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol

Oral

ALENDRONATE PLUS D3 70mg/70ug APOTEX

MP NP

C6307 C6315 C6320

Alendronate Plus D3 Sandoz

MP NP

C6307 C6315 C6320

Alendronate plus D3‑DRLA

MP NP

C6307 C6315 C6320

FonatPlus

MP NP

C6307 C6315 C6320

Fosamax Plus

MP NP

C6307 C6315 C6320

Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol

Oral

ALENDRONATE PLUS D3 70mg/140ug APOTEX

MP NP

C6306 C6319 C6325

Alendronate Plus D3 Sandoz

MP NP

C6306 C6319 C6325

Alendronate plus D3‑DRLA

MP NP

C6306 C6319 C6325

FonatPlus

MP NP

C6306 C6319 C6325

Fosamax Plus 70 mg/140 mcg

MP NP

C6306 C6319 C6325

Alirocumab

Injection 75 mg in 1 mL single use pre‑filled pen

Injection

Praluent

C12008 C12010 C12011 C12054 C12055

Injection 150 mg in 1 mL single use pre‑filled pen

Injection

Praluent

C12008 C12010 C12011 C12054 C12055

Allopurinol

Tablet 100 mg

Oral

Allopurinol APOTEX

MP NP

200

Allopurinol Sandoz

MP NP

200

Allosig

MP NP

200

NOUMED ALLOPURINOL

MP NP

200

Progout 100

MP NP

200

Zyloprim

MP NP

200

Tablet 300 mg

Oral

Allopurinol APOTEX

MP NP

Allopurinol Sandoz

MP NP

Allosig

MP NP

NOUMED ALLOPURINOL

MP NP

Progout 300

MP NP

Zyloprim

MP NP

Alogliptin

Tablet 6.25 mg (as benzoate)

Oral

Nesina

MP NP

C4349

Tablet 12.5 mg (as benzoate)

Oral

Nesina

MP NP

C4349

Tablet 25 mg (as benzoate)

Oral

Nesina

MP NP

C4349

Alogliptin with metformin

Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride

Oral

Nesina Met 12.5/1000

MP NP

C4423 C4427

Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride

Oral

Nesina Met 12.5/500

MP NP

C4423 C4427

Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride

Oral

Nesina Met 12.5/850

MP NP

C4423 C4427

Alprazolam

Tablet 250 micrograms

Oral

Kalma 0.25

MP NP

C6773

Tablet 500 micrograms

Oral

Alprax 0.5

MP NP

C6773

Kalma 0.5

MP NP

C6773

Tablet 1 mg

Oral

Alprax 1

MP NP

C6773

Kalma 1

MP NP

C6773

Amantadine

Capsule containing amantadine hydrochloride 100 mg

Oral

Symmetrel 100

MP NP

C5132

100

Ambrisentan

Tablet 5 mg

Oral

Ambrisentan Mylan

See Note 3

D(100)

Cipla Ambrisentan

See Note 3

D(100)

PULMORIS

See Note 3

D(100)

Volibris

See Note 3

D(100)

Tablet 10 mg

Oral

Ambrisentan Mylan

See Note 3

D(100)

Cipla Ambrisentan

See Note 3

D(100)

PULMORIS

See Note 3

D(100)

Volibris

See Note 3

D(100)

Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids

Oral powder 400 g (Neocate Syneo)

Oral

Neocate Syneo

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4368 P4414

Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine

Sachets containing oral powder 20 g, 30 (PKU Go)

Oral

PKU Go

MP NP

C4295

Amino acid formula with carbohydrate without phenylalanine

Tablets containing 0.92 g protein, 462 (PKU Easy Tablet)

Oral

PKU Easy Tablet

MP NP

C4295

Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexanoic acid

Oral liquid 125 mL, 36 (HCU Anamix junior LQ)

Oral

HCU Anamix junior LQ

MP NP

C5534

Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine

Bottles containing oral powder 34 g, 30 (PKU Easy Shake & Go)

Oral

PKU Easy Shake & Go

MP NP

C5970

Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine

Bottles containing oral powder 34 g, 30 (TYR Easy Shake & Go)

Oral

TYR Easy Shake & Go

MP NP

C5533

Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexanoic acid

Oral liquid 125 mL, 36 (TYR Anamix junior LQ)

Oral

TYR Anamix junior LQ

MP NP

C5533

Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides

Oral powder 400 g (Alfamino Junior)

Oral

Alfamino Junior

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974

Oral powder 400 g (Neocate Junior)

Oral

Neocate Junior

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974

Oral powder 800 g (Essential Care Jr)

Oral

Essential Care Jr

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974

Amino acid formula with fat, carbohydrate without methionine

Tablets containing 0.91 g protein, 462 (HCU Easy Tablet)

Oral

HCU Easy Tablet

MP NP

C5534

Amino acid formula with fat, carbohydrate without phenylalanine

Tablets (modified release), 70.8 g protein per 100 g, 110 g, 4 (PKU Easy Microtabs)

Oral

PKU Easy Microtabs

MP NP

C5970

Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine

Tablets containing 0.91 g protein, 462 (TYR Easy Tablet)

Oral

TYR Easy Tablet

MP NP

C5533

Amino acid formula with fat, carbohydrate without valine, leucine and isoleucine

Tablets containing 0.91 g protein, 462 (MSUD Easy Tablet)

Oral

MSUD Easy Tablet

MP NP

C5571

Amino acid formula without phenylalanine

Tablets 1 g, 75 (Phlexy‑10)

Oral

Phlexy‑10

MP NP

C4295

Amino acid formula without valine, leucine and isoleucine

Sachets containing oral powder 6 g, 30 (MSUD amino5)

Oral

MSUD amino5

MP NP

C5571

Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid

Sachets containing oral powder 12.5 g, 30 (PKU Anamix First Spoon)

Oral

PKU Anamix First Spoon

MP NP

C4295

Sachets containing oral powder 12.5 g, 30 (PKU Explore 5)

Oral

PKU Explore 5

MP NP

C4295

Sachets containing oral powder 25 g, 30 (PKU Explore 10)

Oral

PKU Explore 10

MP NP

C4295

Amino acid formula with vitamins and minerals without lysine and low in tryptophan

Oral powder 400 g (GA1 Anamix infant)

Oral

GA1 Anamix infant

MP NP

C5323

Oral powder 500 g (XLYS, LOW TRY Maxamum)

Oral

XLYS, LOW TRY Maxamum

MP NP

C5323

Sachets containing oral powder 18 g, 30 (GA1 Anamix Junior)

Oral

GA1 Anamix Junior

MP NP

C6007

Sachets containing oral powder 24 g, 30 (GA gel)

Oral

GA gel

MP NP

C5323 C11482

Sachets containing oral powder 25 g, 30 (GA express 15)

Oral

GA express 15

MP NP

C5323 C11482

Amino acid formula with vitamins and minerals without methionine

Oral liquid 87 mL, 30 (HCU cooler 10)

Oral

HCU cooler 10

MP NP

C5534

Oral liquid 125 mL, 30 (HCU Lophlex LQ 20)

Oral

HCU Lophlex LQ 20

MP NP

C5534

Oral liquid 130 mL, 30 (HCU cooler 15)

Oral

HCU cooler 15

MP NP

C5534

Oral liquid 174 mL, 30 (HCU cooler 20)

Oral

HCU cooler 20

MP NP

C5534

Oral powder 400 g (HCU Anamix infant)

Oral

HCU Anamix infant

MP NP

C5559

Oral powder 500 g (XMET Maxamum)

Oral

XMET Maxamum

MP NP

C5534

Sachets containing oral powder 24 g, 30 (HCU gel)

Oral

HCU gel

MP NP

C5534

Sachets containing oral powder 25 g, 30 (HCU express 15)

Oral

HCU express 15

MP NP

C5534

Sachets containing oral powder 29 g, 30 (HCU Lophlex)

Oral

HCU Lophlex

MP NP

C6038

Sachets containing oral powder 36 g, 30 (HCU Anamix Junior)

Oral

HCU Anamix Junior

MP NP

C6038

Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine

Oral powder 400 g (MMA/PA Anamix infant)

Oral

MMA/PA Anamix infant

MP NP

C5542 C5560

Oral powder 500 g (XMTVI Maxamum)

Oral

XMTVI Maxamum

MP NP

C5542 C5560

Sachets containing oral powder 18 g, 30 (MMA/PA Anamix Junior)

Oral

MMA/PA Anamix Junior

MP NP

C5986 C6055

Sachets containing oral powder 24 g, 30 (MMA/PA gel)

Oral

MMA/PA gel

MP NP

C5542 C5560

Sachets containing oral powder 25 g, 30 (MMA/PA express 15)

Oral

MMA/PA express 15

MP NP

C5542 C5560

Amino acid formula with vitamins and minerals without phenylalanine

Oral liquid 62.5 mL, 60 (PKU Lophlex LQ 10)

Oral

PKU Lophlex LQ 10

MP NP

C4295

Oral liquid 87 mL, 30 (PKU Cooler 10)

Oral

PKU Cooler 10

MP NP

C4295

Oral liquid 125 mL, 30 (PKU Lophlex LQ 20)

Oral

PKU Lophlex LQ 20

MP NP

C4295

Oral liquid 125 mL, 36 (PKU Anamix Junior LQ)

Oral

PKU Anamix Junior LQ

MP NP

C4295

Oral liquid 130 mL, 30 (PKU Air 15)

Oral

PKU Air 15

MP NP

C4295

Oral liquid 130 mL, 30 (PKU Cooler 15)

Oral

PKU Cooler 15

MP NP

C4295

Oral liquid 174 mL, 30 (PKU Air 20)

Oral

PKU Air 20

MP NP

C4295

Oral liquid 174 mL, 30 (PKU Cooler 20)

Oral

PKU Cooler 20

MP NP

C4295

Oral liquid 250 mL (Easiphen)

Oral

Easiphen

MP NP

C4295

Oral gel 85 g, 30 (PKU squeezie)

Oral

PKU squeezie

MP NP

C4295

Oral semi‑solid 109 g, 36 (PKU Lophlex Sensation 20)

Oral

PKU Lophlex Sensation 20

MP NP

C4295

Oral powder 500 g (XP Maxamum)

Oral

XP Maxamum

MP NP

C4295

Sachets containing oral powder 24 g, 30 (PKU gel)

Oral

PKU gel

MP NP

C4295

Sachets containing oral powder 25 g, 30 (PKU express 15)

Oral

PKU express 15

MP NP

C4295

Sachets containing oral powder 28 g, 30 (PKU Lophlex)

Oral

PKU Lophlex

MP NP

C4295

Sachets containing oral powder 34 g, 30 (PKU express 20)

Oral

PKU express 20

MP NP

C4295

Sachets containing oral powder 36 g, 30 (PKU Anamix Junior)

Oral

PKU Anamix Junior

MP NP

C4964

Amino acid formula with vitamins and minerals without phenylalanine and tyrosine

Oral liquid 87 mL, 30 (TYR cooler 10)

Oral

TYR cooler 10

MP NP

C5533

Oral liquid 125 mL, 30 (TYR Lophlex LQ 20)

Oral

TYR Lophlex LQ 20

MP NP

C5533

Oral liquid 130 mL, 30 (TYR cooler 15)

Oral

TYR cooler 15

MP NP

C5533

Oral liquid 174 mL, 30 (TYR cooler 20)

Oral

TYR cooler 20

MP NP

C5533

Oral powder 400 g (TYR Anamix infant)

Oral

TYR Anamix infant

MP NP

C5533

Oral powder 500 g (XPhen, Tyr Maxamum)

Oral

XPhen, Tyr Maxamum

MP NP

C5533

Sachets containing oral powder 24 g, 30 (TYR gel)

Oral

TYR gel

MP NP

C5533

Sachets containing oral powder 25 g, 30 (TYR express 15)

Oral

TYR express 15

MP NP

C5533

Sachets containing oral powder 28 g, 30 (TYR Lophlex)

Oral

TYR Lophlex

MP NP

C5533

Sachets containing oral powder 36 g, 30 (TYR Anamix Junior)

Oral

TYR Anamix Junior

MP NP

C4923

Amino acid formula with vitamins and minerals without valine, leucine and isoleucine

Oral liquid 87 mL, 30 (MSUD cooler 10)

Oral

MSUD cooler 10

MP NP

C5571

Oral liquid 125 mL, 30 (MSUD Lophlex LQ 20)

Oral

MSUD Lophlex LQ 20

MP NP

C5571

Oral liquid 130 mL, 30 (MSUD cooler 15)

Oral

MSUD cooler 15

MP NP

C5571

Oral liquid 174 mL, 30 (MSUD cooler 20)

Oral

MSUD cooler 20

MP NP

C5571

Oral powder 400 g (MSUD Anamix infant)

Oral

MSUD Anamix infant

MP NP

C5571

Oral powder 500 g (MSUD AID III)

Oral

MSUD AID III

MP NP

C5571

Oral powder 500 g (MSUD Maxamum)

Oral

MSUD Maxamum

MP NP

C5571

Sachets containing oral powder 24 g, 30 (MSUD gel)

Oral

MSUD gel

MP NP

C5571

Sachets containing oral powder 25 g, 30 (MSUD express 15)

Oral

MSUD express 15

MP NP

C5571

Sachets containing oral powder 28 g, 30 (MSUD Lophlex)

Oral

MSUD Lophlex

MP NP

C5571

Sachets containing oral powder 36 g, 30 (MSUD Anamix Junior)

Oral

MSUD Anamix Junior

MP NP

C4954

Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexanoic acid

Oral liquid 125 mL, 36 (MSUD Anamix Junior LQ)

Oral

MSUD Anamix Junior LQ

MP NP

C5571

Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine

Oral powder 400 g (PKU Anamix infant)

Oral

PKU Anamix infant

MP NP

C4295

Oral powder 400 g (PKU Start)

Oral

PKU Start

MP NP

C4295

Amino acids‑synthetic, formula

Oral powder 400 g (EleCare)

Oral

EleCare

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4368 P4414

Oral powder 400 g (Neocate Junior Vanilla)

Oral

Neocate Junior Vanilla

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4368 P4414

Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids

Oral powder 400 g (EleCare LCP)

Oral

EleCare LCP

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415

Oral powder 400 g (Neocate LCP)

Oral

Neocate LCP

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415

Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides

Oral powder 400 g (Alfamino)

Oral

Alfamino

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974

Oral powder 400 g (Neocate Gold)

Oral

Neocate Gold

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415

MP NP

C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415

P4368 P4414

Amiodarone

Tablet containing amiodarone hydrochloride 100 mg

Oral

Aratac 100

MP NP

C5665

Cordarone X 100

MP NP

C5665

Tablet containing amiodarone hydrochloride 200 mg

Oral

Amdarone

MP NP

C5665

Amiodarone Sandoz

MP NP

C5665

APO‑Amiodarone

MP NP

C5665

Aratac 200

MP NP

C5665

Cordarone X 200

MP NP

C5665

Rithmik 200

MP NP

C5665

Amisulpride

Oral solution 100 mg per mL, 60 mL

Oral

Solian Solution

MP NP

C4246

Tablet 100 mg

Oral

Amisulpride 100 Winthrop

MP NP

C4246

Amisulpride Sandoz Pharma

MP NP

C4246

APO‑Amisulpride

MP NP

C4246

Solian 100

MP NP

C4246

Sulprix

MP NP

C4246

Tablet 200 mg

Oral

Amisulpride 200 Winthrop

MP NP

C4246

Amisulpride Sandoz Pharma

MP NP

C4246

APO‑Amisulpride

MP NP

C4246

Solian 200

MP NP

C4246

Sulprix

MP NP

C4246

Tablet 400 mg

Oral

Amipride 400

MP NP

C4246

Amisulpride 400 Winthrop

MP NP

C4246

Amisulpride Sandoz Pharma

MP NP

C4246

APO‑Amisulpride

MP NP

C4246

Solian 400

MP NP

C4246

Sulprix

MP NP

C4246

Amitriptyline

Tablet containing amitriptyline hydrochloride 10 mg

Oral

Amitriptyline Alphapharm 10

MP NP

Amitriptyline Lupin

MP NP

APO‑Amitriptyline 10

MP NP

APX‑Amitriptyline

MP NP

Endep 10

MP NP

ENTRIP

MP NP

Tablet containing amitriptyline hydrochloride 25 mg

Oral

Amitriptyline Alphapharm 25

MP NP

Amitriptyline Lupin

MP NP

APO‑Amitriptyline 25

MP NP

APX‑Amitriptyline

MP NP

Endep 25

MP NP

ENTRIP

MP NP

Tablet containing amitriptyline hydrochloride 50 mg

Oral

Amitriptyline Alphapharm 50

MP NP

Amitriptyline Lupin

MP NP

APO‑Amitriptyline 50

MP NP

APX‑Amitriptyline

MP NP

Endep 50

MP NP

ENTRIP

MP NP

Amlodipine

Tablet 5 mg (as besilate)

Oral

Amlo 5

MP NP

Amlodipine Amneal

MP NP

Amlodipine APOTEX

MP NP

Amlodipine GH

MP NP

Amlodipine Sandoz

MP NP

APO‑Amlodipine

MP NP

Blooms the Chemist Amlodipine

MP NP

BTC Amlodipine

MP NP

Nordip

MP NP

Norvapine

MP NP

Norvasc

MP NP

NOUMED AMLODIPINE

MP NP

Pharmacor Amlodipine

MP NP

Tablet 10 mg (as besilate)

Oral

Amlo 10

MP NP

Amlodipine Amneal

MP NP

Amlodipine APOTEX

MP NP

Amlodipine GH

MP NP

Amlodipine Sandoz

MP NP

APO‑Amlodipine

MP NP

Blooms the Chemist Amlodipine

MP NP

BTC Amlodipine

MP NP

Nordip

MP NP

Norvapine

MP NP

Norvasc

MP NP

NOUMED AMLODIPINE

MP NP

Pharmacor Amlodipine

MP NP

Amlodipine with atorvastatin

Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium)

Oral

Cadivast 5/10

MP NP

Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium)

Oral

Cadivast 5/20

MP NP

Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)

Oral

Cadivast 5/40

MP NP

Caduet 5/40

MP NP

Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)

Oral

Cadivast 5/80

MP NP

Caduet 5/80

MP NP

Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium)

Oral

Cadivast 10/10

MP NP

Caduet 10/10

MP NP

Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium)

Oral

Cadivast 10/20

MP NP

Caduet 10/20

MP NP

Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)

Oral

Cadivast 10/40

MP NP

Caduet 10/40

MP NP

Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)

Oral

Cadivast 10/80

MP NP

Caduet 10/80

MP NP

Amlodipine with valsartan

Tablet 5 mg (as besilate)‑80 mg

Oral

Exforge 5/80

MP NP

C4373

Valsartan/Amlodipine Novartis 80/5

MP NP

C4373

Tablet 5 mg (as besilate)‑160 mg

Oral

Exforge 5/160

MP NP

C4373

Valsartan/Amlodipine Novartis 160/5

MP NP

C4373

Tablet 5 mg (as besilate)‑320 mg

Oral

Exforge 5/320

MP NP

C4373

Valsartan/Amlodipine Novartis 320/5

MP NP

C4373

Tablet 10 mg (as besilate)‑160 mg

Oral

Exforge 10/160

MP NP

C4373

Valsartan/Amlodipine Novartis 160/10

MP NP

C4373

Tablet 10 mg (as besilate)‑320 mg

Oral

Exforge 10/320

MP NP

C4373

Valsartan/Amlodipine Novartis 320/10

MP NP

C4373

Amlodipine with valsartan and hydrochlorothiazide

Tablet 5 mg (as besilate)‑160 mg‑12.5 mg

Oral

Exforge HCT 5/160/12.5

MP NP

C4311

Valsartan/Amlodipine/HCT Novartis 160/5/12.5

MP NP

C4311

Tablet 5 mg (as besilate)‑160 mg‑25 mg

Oral

Exforge HCT 5/160/25

MP NP

C4311

Valsartan/Amlodipine/HCT Novartis 160/5/25

MP NP

C4311

Tablet 10 mg (as besilate)‑160 mg‑12.5 mg

Oral

Exforge HCT 10/160/12.5

MP NP

C4311

Valsartan/Amlodipine/HCT Novartis 160/10/12.5

MP NP

C4311

Tablet 10 mg (as besilate)‑160 mg‑25 mg

Oral

Exforge HCT 10/160/25

MP NP

C4311

Valsartan/Amlodipine/HCT Novartis 160/10/25

MP NP

C4311

Tablet 10 mg (as besilate)‑320 mg‑25 mg

Oral

Exforge HCT 10/320/25

MP NP

C4311

Valsartan/Amlodipine/HCT Novartis 320/10/25

MP NP

C4311

Amoxicillin

Capsule 250 mg (as trihydrate)

Oral

Alphamox 250

MP NP MW PDP

AMILOXYN

MP NP MW PDP

Amoxil

MP NP MW PDP

APO‑Amoxycillin

MP NP MW PDP

Cilamox

MP NP MW PDP

Alphamox 250

MP NP

P10404

40
CN10404

0
CN10404

AMILOXYN

MP NP

P10404

40
CN10404

0
CN10404

Amoxil

MP NP

P10404

40
CN10404

0
CN10404

APO‑Amoxycillin

MP NP

P10404

40
CN10404

0
CN10404

Cilamox

MP NP

P10404

40
CN10404

0
CN10404

Capsule 500 mg (as trihydrate)

Oral

Alphamox 500

MP NP MW PDP

AMILOXYN

MP NP MW PDP

Amoxil

MP NP MW PDP

Amoxycillin generichealth 500

MP NP MW PDP

Amoxycillin Sandoz

MP NP MW PDP

APO‑Amoxycillin

MP NP MW PDP

Cilamox

MP NP MW PDP

NOUMED AMOXICILLIN

MP NP MW PDP

Alphamox 500

MP NP

P10402

40
CN10402

0
CN10402

AMILOXYN

MP NP

P10402

40
CN10402

0
CN10402

Amoxil

MP NP

P10402

40
CN10402

0
CN10402

Amoxycillin generichealth 500

MP NP

P10402

40
CN10402

0
CN10402

Amoxycillin Sandoz

MP NP

P10402

40
CN10402

0
CN10402

APO‑Amoxycillin

MP NP

P10402

40
CN10402

0
CN10402

Cilamox

MP NP

P10402

40
CN10402

0
CN10402

NOUMED AMOXICILLIN

MP NP

P10402

40
CN10402

0
CN10402

Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL

Oral

Amoxil

PDP

MP NP

P5863

1
CN5863

Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL

Oral

Alphamox 125

PDP

Amoxil

PDP

APO‑Amoxycillin

PDP

NOUMED AMOXICILLIN

PDP

Alphamox 125

MP NP

Amoxil

MP NP

APO‑Amoxycillin

MP NP

NOUMED AMOXICILLIN

MP NP

Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL

Oral

Alphamox 250

PDP

Amoxil Forte

PDP

Amoxycillin Sandoz

PDP

APO‑Amoxycillin

PDP

Cilamox

PDP

NOUMED AMOXICILLIN

PDP

Alphamox 250

MP NP

Amoxil Forte

MP NP

Amoxycillin Sandoz

MP NP

APO‑Amoxycillin

MP NP

Cilamox

MP NP

NOUMED AMOXICILLIN

MP NP

Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL

Oral

Maxamox

PDP

MP NP

Tablet 1 g (as trihydrate)

Oral

Amoxycillin Sandoz

MP NP

C5843 C10416

Maxamox

MP NP

C5843 C10416

Amoxicillin with clavulanic acid

Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL

Oral

Curam

PDP

C5833 C5894

MP NP

C5832 C5893

Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL

Oral

Augmentin Duo 400

PDP

C5833 C5894

Curam Duo

PDP

C5833 C5894

Augmentin Duo 400

MP NP

C5832 C5893

Curam Duo

MP NP

C5832 C5893

Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

Oral

AlphaClav Duo

MP NP

C5832 C5893 C10405

P5832 P5893

C5832 C5893

PDP

C5833 C5894

AMCLAVOX DUO 500/125

MP NP

C5832 C5893 C10405

P5832 P5893

C5832 C5893

PDP

C5833 C5894

Amoxycillin/Clavulanic Acid 500/125 APOTEX

MP NP

C5832 C5893 C10405

P5832 P5893

C5832 C5893

PDP

C5833 C5894

Amoxyclav AN 500/125

MP NP

C5832 C5893 C10405

P5832 P5893

C5832 C5893

PDP

C5833 C5894

APO‑Amoxycillin/ Clavulanic Acid 500/125

MP NP

C5832 C5893 C10405

P5832 P5893

C5832 C5893

PDP

C5833 C5894

Augmentin Duo

MP NP

C5832 C5893 C10405

P5832 P5893

C5832 C5893

PDP

C5833 C5894

Curam Duo 500/125

MP NP

C5832 C5893 C10405

P5832 P5893

C5832 C5893

PDP

C5833 C5894

AlphaClav Duo

MP NP

C5832 C5893 C10405

P10405

AMCLAVOX DUO 500/125

MP NP

C5832 C5893 C10405

P10405

Amoxycillin/Clavulanic Acid 500/125 APOTEX

MP NP

C5832 C5893 C10405

P10405

Amoxyclav AN 500/125

MP NP

C5832 C5893 C10405

P10405

APO‑Amoxycillin/ Clavulanic Acid 500/125

MP NP

C5832 C5893 C10405

P10405

Augmentin Duo

MP NP

C5832 C5893 C10405

P10405

Curam Duo 500/125

MP NP

C5832 C5893 C10405

P10405

Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

Oral

AlphaClav Duo Forte

MP NP

C5832 C5893 C10413

P5832 P5893

PDP

C5833 C5894

AMCLAVOX DUO FORTE 875/125

MP NP

C5832 C5893 C10413

P5832 P5893

PDP

C5833 C5894

Amoxyclav AN 875/125

MP NP

C5832 C5893 C10413

P5832 P5893

PDP

C5833 C5894

AmoxyClav generichealth 875/125

MP NP

C5832 C5893 C10413

P5832 P5893

PDP

C5833 C5894

APO‑Amoxycillin and Clavulanic Acid

MP NP

C5832 C5893 C10413

P5832 P5893

PDP

C5833 C5894

Augmentin Duo forte

MP NP

C5832 C5893 C10413

P5832 P5893

PDP

C5833 C5894

Curam Duo Forte 875/125

MP NP

C5832 C5893 C10413

P5832 P5893

PDP

C5833 C5894

AlphaClav Duo Forte

MP NP

C5832 C5893 C10413

P10413

AMCLAVOX DUO FORTE 875/125

MP NP

C5832 C5893 C10413

P10413

Amoxyclav AN 875/125

MP NP

C5832 C5893 C10413

P10413

AmoxyClav generichealth 875/125

MP NP

C5832 C5893 C10413

P10413

APO‑Amoxycillin and Clavulanic Acid

MP NP

C5832 C5893 C10413

P10413

Augmentin Duo forte

MP NP

C5832 C5893 C10413

P10413

Curam Duo Forte 875/125

MP NP

C5832 C5893 C10413

P10413

Amphotericin B

Lozenge 10 mg

Oral

Fungilin

PDP

MP NP

Ampicillin

Powder for injection 500 mg (as sodium)

Injection

Austrapen

PDP

MP NP

Powder for injection 1 g (as sodium)

Injection

Ampicyn

PDP

MP NP

Amylopectin, modified long chain

Sachets containing oral powder 60 g, 30 (Glycosade)

Oral

Glycosade

MP NP

C5561

Anakinra

Injection 100 mg in 0.67 mL single use pre‑filled syringe

Injection

Kineret

C5450

D(100)

Anastrozole

Tablet 1 mg

Oral

Anastrol

MP NP

C5464

Anastrozole FBM

MP NP

C5464

Anastrozole GH

MP NP

C5464

Anastrozole Sandoz

MP NP

C5464

APO‑Anastrozole

MP NP

C5464

Arianna 1

MP NP

C5464

Arimidex

MP NP

C5464

Apixaban

Tablet 2.5 mg

Oral

Eliquis

MP NP

C4132 C4269 C4359 C4381 C4382 C4402 C4409

P4359 P4381

MP NP

C4132 C4269 C4359 C4381 C4382 C4402 C4409

P4382 P4409

MP NP

C4132 C4269 C4359 C4381 C4382 C4402 C4409

P4402

MP NP

C4132 C4269 C4359 C4381 C4382 C4402 C4409

P4132 P4269

Tablet 5 mg

Oral

Eliquis

MP NP

C4098 C4099 C4269 C5083 C5098

P4098 P5098

MP NP

C4098 C4099 C4269 C5083 C5098

P4099 P4269 P5083

Apomorphine

Injection containing apomorphine hydrochloride hemihydrate 20 mg in 2 mL

Injection

Movapo

MP NP

C10844

360

C11385 C11445

360

C(100)

Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL

Injection

Movapo

MP NP

C10844

180

C11385 C11445

180

C(100)

Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL

Injection

Apomine Solution for Infusion

MP NP

C10844

C10830 C10863

C(100)

Schedule 6—Pharmaceutical items with modified prescription circumstances during COVID‑19 pandemic

Note: See section 10A.

Pharmaceutical items with modified prescription circumstances during COVID-19 pandemic
Listed drug	Form	Manner of administration
Abatacept	Injection 125 mg in 1 mL single dose autoinjector	Injection
Abatacept	Injection 125 mg in 1 mL single dose pre‑filled syringe	Injection
Abatacept	Powder for I.V. infusion 250 mg	Injection
Adalimumab	Injection 20 mg in 0.2 mL pre-filled syringe	Injection
Adalimumab	Injection 20 mg in 0.4 mL pre‑filled syringe	Injection
Adalimumab	Injection 40 mg in 0.4 mL pre-filled pen	Injection
Adalimumab	Injection 40 mg in 0.4 mL pre-filled syringe	Injection
Adalimumab	Injection 40 mg in 0.8 mL pre‑filled syringe	Injection
Adalimumab	Injection 40 mg in 0.8 mL pre‑filled pen	Injection
Adalimumab	Injection 80 mg in 0.8 mL pre-filled pen	Injection
Adalimumab	Injection 80 mg in 0.8 mL pre-filled syringe	Injection
Ambrisentan	Tablet 5 mg	Oral
Ambrisentan	Tablet 10 mg	Oral
Baricitinib	Tablet 2 mg	Oral
Baricitinib	Tablet 4 mg	Oral
Benralizumab	Injection 30 mg in 1 mL single dose pre‑filled pen	Injection
Bosentan	Tablet 62.5 mg (as monohydrate)	Oral
Bosentan	Tablet 125 mg (as monohydrate)	Oral
Certolizumab pegol	Injection 200 mg in 1 mL single use pre‑filled syringe	Injection
Certolizumab pegol	Solution for injection 200 mg in 1 mL pre‑filled pen	Injection
Dornase alfa	Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL	Inhalation
Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium)	Injection
Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL	Injection
Epoprostenol	Powder for I.V. infusion 1.5 mg (as sodium)	Injection
Epoprostenol	Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL	Injection
Etanercept	Injection set containing 4 vials powder for injection 25 mg and 4 pre‑filled syringes solvent 1 mL	Injection
Etanercept	Injection 50 mg in 1 mL single use auto‑injector, 4	Injection
Etanercept	Injection 50 mg in 1 mL single use dose-dispenser cartridges, 4	Injection
Etanercept	Injections 50 mg in 1 mL single use pre‑filled syringes, 4	Injection
Golimumab	Injection 50 mg in 0.5 mL single use pre‑filled pen	Injection
Golimumab	Injection 50 mg in 0.5 mL single use pre‑filled syringe	Injection
Golimumab	Injection 100 mg in 1 mL single use pre‑filled pen	Injection
Guselkumab	Injection 100 mg in 1 mL single use pre-filled pen	Injection
Guselkumab	Injection 100 mg in 1 mL single use pre‑filled syringe	Injection
Iloprost	Solution for inhalation 20 micrograms (as trometamol) in 2 mL	Inhalation
Infliximab	Powder for I.V. infusion 100 mg	Injection
Infliximab	Solution for injection 120 mg in 1 mL pre-filled pen	Injection
Infliximab	Solution for injection 120 mg in 1 mL pre-filled syringe	Injection
Ivacaftor	Sachet containing granules 50 mg	Oral
Ivacaftor	Sachet containing granules 75 mg	Oral
Ivacaftor	Tablet 150 mg	Oral
Ixekizumab	Injection 80 mg in 1 mL single dose pre‑filled pen	Injection
Lenalidomide	Capsule 5 mg	Oral
Lenalidomide	Capsule 10 mg	Oral
Lenalidomide	Capsule 15 mg	Oral
Lenalidomide	Capsule 25 mg	Oral
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg	Oral
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg	Oral
Lumacaftor with ivacaftor	Tablet containing lumacaftor 100 mg with ivacaftor 125 mg	Oral
Lumacaftor with ivacaftor	Tablet containing lumacaftor 200 mg with ivacaftor 125 mg	Oral
Macitentan	Tablet 10 mg	Oral
Mannitol	Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers	Inhalation by mouth
Mepolizumab	Powder for injection 100 mg	Injection
Mepolizumab	Injection 100 mg in 1 mL single dose pre-filled pen	Injection
Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral
Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral
Nintedanib	Capsule 100 mg	Oral
Nintedanib	Capsule 150 mg	Oral
Omalizumab	Injection 75 mg in 0.5 mL single dose pre‑filled syringe	Injection
Omalizumab	Injection 150 mg in 1 mL single dose pre‑filled syringe	Injection
Pirfenidone	Capsule 267 mg	Oral
Pirfenidone	Tablet 267 mg	Oral
Pirfenidone	Tablet 801mg	Oral
Pomalidomide	Capsule 3 mg	Oral
Pomalidomide	Capsule 4 mg	Oral
Riociguat	Tablet 500 micrograms	Oral
Riociguat	Tablet 1 mg	Oral
Riociguat	Tablet 1.5 mg	Oral
Riociguat	Tablet 2 mg	Oral
Riociguat	Tablet 2.5 mg	Oral
Risankizumab	Injection 75 mg in 0.83 mL pre‑filled syringe	Injection
Rituximab	Solution for I.V. infusion 500 mg in 50 mL	Injection
Secukinumab	Injection 150 mg in 1 mL pre‑filled pen	Injection
Selexipag	Tablet 200 micrograms	Oral
Selexipag	Tablet 400 micrograms	Oral
Selexipag	Tablet 600 micrograms	Oral
Selexipag	Tablet 800 micrograms	Oral
Selexipag	Tablet 1 mg	Oral
Selexipag	Tablet 1.2 mg	Oral
Selexipag	Tablet 1.4 mg	Oral
Selexipag	Tablet 1.6 mg	Oral
Sildenafil	Tablet 20 mg (as citrate)	Oral
Somatropin	Injection 0.4 mg (1.2 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 0.6 mg (1.8 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 0.8 mg (2.4 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1 mg (3 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.2 mg (3.6 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.4 mg (4.2 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.6 mg (4.8 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.8 mg (5.4 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 2 mg (6 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)	Injection
Somatropin	Injection 72 i.u. (24 mg) cartridge with 3.15 mL diluent (with preservative)	Injection
Somatropin	Powder for injection 5 mg (15 i.u.) with diluent in pre‑filled pen (with preservative)	Injection
Somatropin	Powder for injection 12 mg (36 i.u.) with diluent in pre‑filled pen (with preservative)	Injection
Somatropin	Injection 36 i.u. (12 mg) cartridge with 3.15 mL diluent (with preservative)	Injection
Somatropin	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative) in pre‑filled pen	Injection
Somatropin	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)	Injection
Somatropin	Solution for injection 6 mg (18 i.u.) in 1.03 mL cartridge (with preservative)	Injection
Somatropin	Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)	Injection
Somatropin	Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative) in pre‑filled pen	Injection
Somatropin	Solution for injection 10 mg (30 i.u.) in 2 mL cartridge (with preservative)	Injection
Somatropin	Solution for injection 12 mg (36 i.u.) in 1.5 mL cartridge (with preservative)	Injection
Somatropin	Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)	Injection
Somatropin	Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative) in pre‑filled pen	Injection
Somatropin	Solution for injection 20 mg (60 i.u.) in 2.5 mL cartridge (with preservative)	Injection
Tadalafil	Tablet 20 mg	Oral
Tezacaftor with ivacaftor and ivacaftor	Pack containing 28 tablets tezacaftor 100 mg with ivacaftor 150 mg and 28 tablets ivacaftor 150 mg	Oral
Tildrakizumab	Injection 100 mg in 1 mL single dose pre‑filled syringe	Injection
Tocilizumab	Concentrate for injection 80 mg in 4 mL	Injection
Tocilizumab	Concentrate for injection 200 mg in 10 mL	Injection
Tocilizumab	Concentrate for injection 400 mg in 20 mL	Injection
Tocilizumab	Injection 162 mg in 0.9 mL single use pre‑filled pen	Injection
Tocilizumab	Injection 162 mg in 0.9 mL single use pre‑filled syringe	Injection
Tofacitinib	Tablet 5 mg	Oral
Tofacitinib	Tablet 10 mg	Oral
Upadacitinib	Tablet 15 mg	Oral
Ustekinumab	Injection 45 mg in 0.5 mL	Injection
Ustekinumab	Solution for I.V. infusion 130 mg in 26 mL	Injection
Vedolizumab	Injection 108 mg in 0.68 mL single use pre-filled pen	Injection

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

Endnote 2—Abbreviation key

ad = added or inserted	o = order(s)
am = amended	Ord = Ordinance
amdt = amendment	orig = original
c = clause(s)	par = paragraph(s)/subparagraph(s)
C[x] = Compilation No. x	/sub‑subparagraph(s)
Ch = Chapter(s)	pres = present
def = definition(s)	prev = previous
Dict = Dictionary	(prev…) = previously
disallowed = disallowed by Parliament	Pt = Part(s)
Div = Division(s)	r = regulation(s)/rule(s)
ed = editorial change	reloc = relocated
exp = expires/expired or ceases/ceased to have	renum = renumbered
effect	rep = repealed
F = Federal Register of Legislation	rs = repealed and substituted
gaz = gazette	s = section(s)/subsection(s)
LA = Legislation Act 2003	Sch = Schedule(s)
LIA = Legislative Instruments Act 2003	Sdiv = Subdivision(s)
(md) = misdescribed amendment can be given	SLI = Select Legislative Instrument
effect	SR = Statutory Rules
(md not incorp) = misdescribed amendment	Sub‑Ch = Sub‑Chapter(s)
cannot be given effect	SubPt = Subpart(s)
mod = modified/modification	underlining = whole or part not
No. = Number(s)	commenced or to be commenced

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
PB 71 of 2012	28 Sept 2012 (F2012L01982)	1 Oct 2012 (s 2)
PB 93 of 2012	29 Nov 2012 (F2012L02291)	1 Dec 2012 (s 2)	—
PB 108 of 2012	18 Dec 2012 (F2012L02512)	1 Jan 2013 (s 2)	—
PB 1 of 2013	10 Jan 2013 (F2013L00039)	1 Feb 2013 (s 2)	—
PB 4 of 2013	21 Jan 2013 (F2013L00072)	22 Jan 2013 (s 2)	—
PB 8 of 2013	14 Feb 2013 (F2013L00185)	1 Mar 2013 (s 2)	—
PB 14 of 2013	27 Mar 2013 (F2013L00566)	1 Apr 2013 (s 2)	—
PB 21 of 2013	24 Apr 2013 (F2013L00685)	1 May 2013 (s 2)	—
PB 29 of 2013	24 May 2013 (F2013L00843)	1 June 2013 (s 2)	—
PB 35 of 2013	5 June 2013 (F2013L00922)	1 July 2013 (s 2)	—
PB 39 of 2013	21 June 2013 (F2013L01096)	1 July 2013 (s 2)	—
PB 40 of 2013	29 July 2013 (F2013L01460)	1 Aug 2013 (s 2)	—
PB 53 of 2013	16 Aug 2013 (F2013L01580)	1 Sept 2013 (s 2)	—
PB 61 of 2013	10 Sept 2013 (F2013L01682)	1 Oct 2013 (s 2)	—
PB 69 of 2013	4 Oct 2013 (F2013L01768)	1 Nov 2013 (s 2)	—
PB 74 of 2013	29 Nov 2013 (F2013L02013)	1 Dec 2013 (s 2)	—
PB 88 of 2013	20 Dec 2013 (F2013L02170)	1 Jan 2014 (s 2)	—
PB 1 of 2014	10 Jan 2014 (F2014L00051)	1 Feb 2014 (s 2)	—
PB 9 of 2014	17 Feb 2014 (F2014L00147)	1 Mar 2014 (s 2)	—
PB 17 of 2014	26 Mar 2014 (F2014L00342)	1 Apr 2014 (s 2)	—
PB 27 of 2014	11 Apr 2014 (F2014L00399)	1 May 2014 (s 2)	—
PB 36 of 2014	21 May 2014 (F2014L00588)	1 June 2014 (s 2)	—
PB 45 of 2014	20 June 2014 (F2014L00763)	1 July 2014 (s 2)	—
PB 51 of 2014	1 July 2014 (F2014L00921)	1 July 2014 (s 2)	—
PB 52 of 2014	31 July 2014 (F2014L01058)	1 Aug 2014 (s 2)	—
PB 61 of 2014	25 Aug 2014 (F2014L01121)	1 Sept 2014 (s 2)	—
PB 72 of 2014	30 Sept 2014 (F2014L01298)	1 Oct 2014 (s 2)	—
PB 82 of 2014	24 Oct 2014 (F2014L01395)	1 Nov 2014 (s 2)	—
PB 88 of 2014	28 Nov 2014 (F2014L01602)	1 Dec 2014 (s 2)	—
PB 101 of 2014	22 Dec 2014 (F2014L01780)	1 Jan 2015 (s 2)	—
PB 109 of 2014	23 Dec 2014 (F2014L01795)	1 Jan 2015 (s 2)	—
PB 1 of 2015	14 Jan 2015 (F2015L00040)	1 Feb 2015 (s 2)	—
PB 10 of 2015	25 Feb 2015 (F2015L00205)	1 Mar 2015 (s 2)	—
PB 26 of 2015	26 Mar 2015 (F2015L00342)	1 Apr 2015 (s 2)	—
PB 39 of 2015	24 Apr 2015 (F2015L00595)	1 May 2015 (s 2)	—
PB 47 of 2015	29 May 2015 (F2015L00762)	1 June 2015 (s 2)	—
PB 55 of 2015	30 June 2015 (F2015L01058)	1 July 2015 (s 2)	—
PB 68 of 2015	31 July 2015 (F2015L01212)	1 Aug 2015 (s 2)	—
PB 78 of 2015	28 Aug 2015 (F2015L01351)	1 Sept 2015 (s 2)	—
PB 90 of 2015	29 Sept 2015 (F2015L01520)	1 Oct 2015 (s 2)	—
PB 101 of 2015	27 Oct 2015 (F2015L01701)	1 Nov 2015 (s 2)	—
PB 107 of 2015	30 Nov 2015 (F2015L01878)	1 Dec 2015 (s 2)	—
PB 117 of 2015	24 Dec 2015 (F2015L02141)	1 Jan 2016 (s 2)	—
PB 1 of 2016	1 Feb 2016 (F2016L00075)	1 Feb 2016 (s 2)	—
PB 11 of 2016	23 Feb 2016 (F2016L00136)	1 Mar 2016 (s 2)	—
PB 18 of 2016	1 Apr 2016 (F2016L00470)	1 Apr 2016 (s 2)	—
PB 29 of 2016	29 Apr 2016 (F2016L00604)	1 May 2016 (s 2)	—
PB 41 of 2016	30 May 2016 (F2016L00856)	1 June 2016 (s 2)	—
PB 52 of 2016	22 June 2016 (F2016L01056)	1 July 2016 (s 2)	—
PB 62 of 2016	19 July 2016 (F2016L01185)	1 Aug 2016 (s 2)	—
PB 72 of 2016	18 Aug 2016 (F2016L01296)	1 Sept 2016 (s 2)	—
PB 81 of 2016	30 Sept 2016 (F2016L01560)	1 Oct 2016 (s 2)	—
PB 90 of 2016	31 Oct 2016 (F2016L01689)	1 Nov 2016 (s 2)	—
PB 97 of 2016	30 Nov 2016 (F2016L01832)	1 Dec 2016 (s 2)	—
PB 110 of 2016	22 Dec 2016 (F2016L02026)	1 Jan 2017 (s 2)	—
PB 1 of 2017	25 Jan 2017 (F2017L00070)	1 Feb 2017 (s 2)	—
PB 15 of 2017	30 Mar 2017 (F2017L00362)	1 Apr 2017 (s 2)	—
PB 26 of 2017	28 Apr 2017 (F2017L00483)	1 May 2017 (s 2)	—
PB 34 of 2017	31 May 2017 (F2017L00625)	1 June 2017 (s 2)	—
PB 45 of 2017	29 June 2017 (F2017L00825)	1 July 2017 (s 2)	—
PB 55 of 2017	25 July 2017 (F2017L00948)	1 Aug 2017 (s 2)	—
PB 62 of 2017	29 Aug 2017 (F2017L01098)	1 Sept 2017 (s 2)	—
PB 71 of 2017	26 Sept 2017 (F2017L01264)	1 Oct 2017 (s 2)	—
PB 84 of 2017	23 Oct 2017 (F2017L01383)	1 Nov 2017 (s 2)	—
PB 92 of 2017	29 Nov 2017 (F2017L01548)	1 Dec 2017 (s 2)	—
PB 101 of 2017	18 Dec 2017 (F2017L01644)	1 Jan 2018 (s 2)	—
PB 1 of 2018	24 Jan 2018 (F2018L00057)	1 Feb 2018 (s 2)	—
PB 8 of 2018	20 Feb 2018 (F2018L00129)	21 Feb 2018 (s 2)	—
PB 12 of 2018	28 Feb 2018 (F2018L00161)	1 Mar 2018 (s 2)	—
PB 19 of 2018	28 Mar 2018 (F2018L00420)	1 Apr 2018 (s 2)	—
PB 29 of 2018	27 Apr 2018 (F2018L00532)	1 May 2018 (s 2)	—
PB 36 of 2018	31 May 2018 (F2018L00685)	1 June 2018 (s 2)	—
PB 50 of 2018	29 June 2018 (F2018L00956)	1 July 2018 (s 2)	—
PB 63 of 2018	31 July 2018 (F2018L01071)	1 Aug 2018 (s 2)	—
PB 74 of 2018	30 Aug 2018 (F2018L01223)	1 Sept 2018 (s 2)	—
PB 83 of 2018	27 Sept 2018 (F2018L01359)	1 Oct 2018 (s 2)	—
PB 91 of 2018	29 Oct 2018 (F2018L01491)	1 Nov 2018 (s 2)	—
PB 99 of 2018	29 Nov 2018 (F2018L01625)	1 Dec 2018 (s 2)	—
PB 110 of 2018	19 Dec 2018 (F2018L01802)	1 Jan 2019 (s 2)	—
PB 1 of 2019	31 Jan 2019 (F2019L00073)	1 Feb 2019 (s 2)	—
PB 10 of 2019	27 Feb 2019 (F2019L00211)	1 Mar 2019 (s 2)	—
PB 17 of 2019	29 Mar 2019 (F2019L00472)	1 Apr 2019 (s 2)	—
PB 28 of 2019	30 Apr 2019 (F2019L00663)	1 May 2019 (s 2)	—
PB 36 of 2019	31 May 2019 (F2019L00713)	1 June 2019 (s 2)	—
PB 46 of 2019	28 June 2019 (F2019L00907)	1 July 2019 (s 2)	—
PB 58 of 2019	30 July 2019 (F2019L01020)	1 Aug 2019 (s 2)	—
PB 66 of 2019	30 Aug 2019 (F2019L01129)	1 Sept 2019 (s 2)	—
PB 76 of 2019	30 Sept 2019 (F2019L01291)	1 Oct 2019 (s 2)	—
PB 84 of 2019	31 Oct 2019 (F2019L01394)	1 Nov 2019 (s 2)	—
PB 92 of 2019	28 Nov 2019 (F2019L01520)	1 Dec 2019 (s 2)	—
PB 104 of 2019	23 Dec 2019 (F2019L01690)	1 Jan 2020 (s 2)	—
PB 1 of 2020	30 Jan 2020 (F2020L00069)	1 Feb 2020 (s 2)	—
PB 14 of 2020	28 Feb 2020 (F2020L00184)	1 Mar 2020 (s 2)	—
PB 20 of 2020	31 Mar 2020 (F2020L00365)	1 Apr 2020 (s 2)	—
PB 32 of 2020	30 Apr 2020 (F2020L00531)	1 May 2020 (s 2(1) item 1)	—
PB 33 of 2020	30 Apr 2020 (F2020L00523)	1 May 2020 (s 2)	—
PB 42 of 2020	29 May 2020 (F2020L00641)	1 June 2020 (s 2)	—
PB 55 of 2020	29 June 2020 (F2020L00841)	1 July 2020 (s 2)	—
PB 67 of 2020	31 July 2020 (F2020L00968)	1 Aug 2020 (s 2)	—
PB 78 of 2020	27 Aug 2020 (F2020L01068)	1 Sept 2020 (s 2)	—
PB 100 of 2020	29 Sept 2020 (F2020L01247)	Sch 1 (items 1, 2): 30 Sept 2020 (s 2(1) item 1))	—
PB 89 of 2020	30 Sept 2020 (F2020L01268)	1 Oct 2020 (s 2)	—
PB 102 of 2020	30 Oct 2020 (F2020L01365)	1 Nov 2020 (s 2)	—
PB 109 of 2020	30 Oct 2020 (F2020L01366)	Sch 1 (items 1–5): 1 Nov 2020 (s 2(1) item 2)	—
PB 111 of 2020	27 Nov 2020 (F2020L01490)	1 Dec 2020 (s 2)	—
PB 124 of 2020	23 Dec 2020 (F2020L01691)	1 Jan 2021 (s 2)	—
PB 1 of 2021	28 Jan 2021 (F2021L00076)	1 Feb 2021 (s 2)	—
PB 13 of 2021	28 Feb 2021 (F2021L00166)	1 Mar 2021 (s 2)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 3) (PB 22 of 2021)	31 Mar 2021 (F2021L00396)	1 Apr 2021 (s 2)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 4) (PB 38 of 2021)	30 Apr 2021 (F2021L00517)	1 May 2021 (s 2)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 5) (PB 46 of 2021)	28 May 2021 (F2021L00654)	1 June 2021 (s 2)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 6) (PB 60 of 2021)	30 June 2021 (F2021L00904)	1 July 2021 (s 2)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 7) (PB 74 of 2021)	31 July 2021 (F2021L01057)	Sch 1: 1 Nov 2020 (s 2(1) item 2) Remainder: 1 Aug 2021 (s 2(1) items 1, 3)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 8) (PB 87 of 2021)	31 Aug 2021 (F2021L01218)	1 Sept 2021 (s 2(1) item 1)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 9) (PB 97 of 2021)	30 Sept 2021 (F2021L01369)	1 Oct 2021 (s 2(1) item 1)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 10) (PB 109 of 2021)	31 Oct 2021 (F2021L01485)	1 Nov 2021 (s 2(1) item 1)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 11) (PB 118 of 2021)	30 Nov 2021 (F2021L01649)	1 Dec 2021 (s 2(1) item 1)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2021 (No. 12) (PB 128 of 2021)	24 Dec 2021 (F2021L01902)	1 Jan 2022 (s 2(1) item 1)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2022 (No. 1) (PB 1 of 2022)	31 Jan 2022 (F2022L00091)	1 Feb 2022 (s 2(1) item 1)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2022 (No. 2) (PB 11 of 2022)	28 Feb 2022 (F2022L00203)	1 Mar 2022 (s 2(1) item 1)	—
National Health Legislation Amendment (Authority Required Procedures for Prescriptions) Instrument 2022 (PB 21 of 2022)	28 Feb 2022 (F2022L00208)	Sch 1 (item 2): 1 Mar 2022 (s 2(1) item 1)	—
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2022 (No. 3) (PB 23 of 2022)	31 Mar 2022 (F2022L00454)	1 Apr 2022 (s 2(1) item 1)	—

Endnote 4—Amendment history

Provision affected	How affected
s 2........................................	rep LIA s 48D
s 3........................................	rep LIA s 48C
s 4........................................	am PB 93 of 2012; PB 26 and 55 of 2015; PB 11 of 2016; PB 83 of 2018
ed C72
am PB 67 of 2020; F2021L01057; F2021L01485
s 9........................................	am PB 8 of 2018; PB 109 of 2020
s 9A.....................................	ad F2021L01057
s 10......................................	am PB 32 of 2020
(3A) rep 1 July 2022 (s 10A(3))
s 10A...................................	ad PB 32 of 2020
am PB 100 of 2020; F2021L00396; F2021L01902
rep 1 July 2022 (s 10A(3))
s 11......................................	am PB 26 of 2015; PB 29 of 2016
s 12......................................	am PB 26 of 2015; PB 29 of 2016; PB 67 of 2020; F2022L00208
s 13......................................	am PB 26 of 2015; PB 29 of 2016
s 14......................................	am PB 26 of 2015
Schedule 1
Schedule 1...........................	am PB 93 and 108 of 2012; PB 1, 4, 8, 14, 21, 29, 35, 39, 40, 53, 61, 69, 74 and 88 of 2013; PB 1, 9, 17, 27, 36, 45, 51, 52, 61, 72, 82, 88, 101 and 109 of 2014; PB 1, 10 and 26 of 2015; PB 39, 47, 55, 68 (Sch 1 par 9(e) md), 78, 90, 101, 107 and 117 of 2015; PB 1, 11, 18, 29, 41, 52, 62, 72, 81 (Sch 1 item 56 md), 90, 97 and 110 of 2016
ed C51
am PB 1 of 2017
ed C53
am PB 15 of 2017; PB 26 of 2017; PB 34 of 2017; PB 45 of 2017 (Sch 1 item 10 md incorp); PB 55 of 2017; PB 62 of 2017; PB 71 of 2017; PB 84 of 2017; PB 92 of 2017; PB 101 of 2017; PB 1 of 2018; PB 12 of 2018; PB 19 of 2018; PB 29 of 2018; PB 36 of 2018
rs PB 50 of 2018
am PB 63 of 2018; PB 74 of 2018; PB 83 of 2018
ed C72
am PB 91 of 2018; PB 99 of 2018; PB 110 of 2018; PB 1 of 2019
ed C76
am PB 10 of 2019; PB 17 of 2019; PB 28 of 2019
ed C79
am PB 36 of 2019; PB 46 of 2019; PB 58 of 2019; PB 66 of 2019
ed C83
am PB 76 of 2019
ed C84
am PB 84 of 2019; PB 92 of 2019; PB 104 of 2019; PB 1 of 2020; PB 14 of 2020; PB 20 of 2020; PB 33 of 2020; PB 42 of 2020; PB 55 of 2020; PB 67 of 2020; PB 78 of 2020; PB 89 of 2020; PB 102 of 2020; PB 109 of 2020; PB 111 of 2020; PB 124 of 2020; PB 1 of 2021; PB 13 of 2021; F2021L00396; F2021L00517; F2021L00654; F2021L00904; F2021L01057; F2021L01218; F2021L01369; F2021L01485; F2021L01649; F2021L01902
ed C112
am F2022L00091; F2022L00203
ed C115
am F2022L00454
ed C116
Schedule 2
Schedule 2...........................	am PB 68 and 90 of 2015; F2021L01057
Schedule 3
Schedule 3...........................	am PB 93 and 108 of 2012; PB 1, 8, 14, 29, 40, 61, 74 and 88 of 2013; PB 1, 9, 17, 36, 45, 52, 61, 72, 82, 88 and 101 of 2014; PB 1, 10, 26, 39, 47, 55, 68, 78, 90, 101, 107 and 117 of 2015; PB 1, 11, 18, 41, 52, 62, 81, 97 and 110 of 2016; PB 1 of 2017; PB 15 of 2017; PB 26 of 2017; PB 34 of 2017; PB 45 of 2017; PB 84 of 2017; PB 92 of 2017; PB 101 of 2017; PB 12 of 2018; PB 19 of 2018; PB 29 of 2018; PB 36 of 2018; PB 63 of 2018; PB 74 of 2018; PB 83 of 2018; PB 91 of 2018; PB 99 of 2018; PB 110 of 2018; PB 1 of 2019; PB 10 of 2019; PB 17 of 2019; PB 28 of 2019; PB 36 of 2019; PB 46 of 2019; PB 58 of 2019
ed C82
am PB 66 of 2019; PB 76 of 2019; PB 84 of 2019; PB 92 of 2019; PB 104 of 2019; PB 14 of 2020; PB 20 of 2020; PB 55 of 2020; PB 67 of 2020; PB 78 of 2020; PB 102 of 2020; PB 111 of 2020; PB 1 of 2021; F2021L00396; F2021L00517; F2021L00904; F2021L01057; F2021L01218; F2021L01369; F2021L01485; F2021L01649; F2021L01902; F2022L00091; F2022L00203; F2022L00454
Schedule 4
Schedule 4...........................	am PB 93 and 108 of 2012; PB 1, 8, 14, 21, 29, 35, 40, 53, 61, 69, 74 and 88 of 2013; PB 1, 9, 17, 27, 36, 45, 52, 61, 72, 82, 88 and 101 of 2014; PB 1, 10, 26, 39, 47, 55, 68, 78, 90, 101, 107 and 117 of 2015; PB 1, 11, 18, 29, 41, 52, 62, 72, 81, 90, 97 and 110 of 2016; PB 1 of 2017; PB 15 of 2017; PB 26 of 2017; PB 34 of 2017 (Sch 1 item 124 md not incorp); PB 45 of 2017; PB 55 of 2017; PB 62 of 2017; PB 71 of 2017; PB 84 of 2017; PB 92 of 2017; PB 101 of 2017; PB 1 of 2018; PB 12 of 2018; PB 19 of 2018; PB 29 of 2018; PB 36 of 2018; PB 50 of 2018; PB 63 of 2018; PB 74 of 2018; PB 83 of 2018; PB 91 of 2018; PB 99 of 2018; PB 110 of 2018; PB 1 of 2019; PB 10 of 2019; PB 17 of 2019; PB 28 of 2019; PB 36 of 2019 (Sch 1 par 50(a), (c), (g)–(i) md not incorp); PB 46 of 2019; PB 58 of 2019; PB 66 of 2019; PB 76 of 2019
ed C84
am PB 84 of 2019; PB 92 of 2019; PB 104 of 2019; PB 1 of 2020; PB 14 of 2020; PB 20 of 2020; PB 33 of 2020; PB 42 of 2020; PB 55 of 2020; PB 67 of 2020; PB 78 of 2020; PB 89 of 2020; PB 102 of 2020; PB 111 of 2020; PB 124 of 2020; PB 1 of 2021; PB 13 of 2021; F2021L00396; F2021L00517; F2021L00654; F2021L00904; F2021L01057; F2021L01218; F2021L01369; F2021L01485
ed C111
am F2021L01649; F2021L01902; F2022L00091; F2022L00203; F2022L00454
Schedule 5
Schedule 5...........................	ad PB 107, 2015
am PB 1, 11, 18, 29, 41, 52, 62, 72, 81, 90 and 97 of 2016; PB 1 of 2017; PB 15 of 2017; PB 26 of 2017; PB 34 of 2017; PB 45 of 2017; PB 55 of 2017; PB 62 of 2017; PB 71 of 2017; PB 84 of 2017; PB 92 of 2017; PB 101 of 2017; PB 1 of 2018; PB 12 of 2018; PB 19 of 2018 (Sch 1 item 127 md not incorp); PB 29 of 2018; PB 36 of 2018
rs PB 50 of 2018
am PB 63 of 2018 (amdt never applied (Sch 1 item 134)); PB 74 of 2018; PB 83 of 2018; PB 91 of 2018; PB 99 of 2018; PB 110 of 2018; PB 1 of 2019; PB 10 of 2019; PB 17 of 2019; PB 28 of 2019
ed C79
am PB 46 of 2019; PB 58 of 2019; PB 66 of 2019; PB 76 of 2019; PB 84 of 2019; PB 92 of 2019; PB 104 of 2019; PB 1 of 2020; PB 14 of 2020
ed C89
am PB 20 of 2020; PB 42 of 2020; PB 55 of 2020; PB 67 of 2020; PB 78 of 2020; PB 89 of 2020; PB 102 of 2020; PB 111 of 2020; PB 124 of 2020; PB 1 of 2021; PB 13 of 2021; F2021L00396; F2021L00517; F2021L00654; F2021L00904; F2021L01057; F2021L01218; F2021L01369; F2021L01485; F2021L01649
ed C112
am F2021L01902; F2022L00091
ed C114
am F2022L00203; F2022L00454
ed C116
Schedule 6
Schedule 6...........................	ad PB 32 of 2020
am PB 42 of 2020; PB 100 of 2020; F2021L00396; F2021L00654; F2021L00904
ed C106
am F2021L01649; F2021L01902; F2022L00203
rep 1 July 2022 (s 10A(3))

Endnote 5—Editorial changes

In preparing this compilation for registration, the following kinds of editorial change(s) were made under the Legislation Act 2003.

Schedule 1, Part 1, entry for Siponimod in the form Tablet 2 mg (as hemifumarate)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 52 of the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2022 (No. 3) (PB 23 of 2022) provides as follows:

[52] Schedule 1, Part 1, entry for Siponimod in the form Tablet 2 mg (as hemifumerate)

omit from the column headed “Circumstances”: C10956

There is no entry for Siponimod in the form Tablet 2 mg (as hemifumerate) in Part 1 of Schedule 1. However, there is an entry for Siponimod in the form Tablet 2 mg (as hemifumarate).

This compilation was editorially changed to omit “C10956” from the column headed “Circumstances” in the entry for Siponimod in the form Tablet 2 mg (as hemifumarate) in Part 1 of Schedule 1 to give effect to the misdescribed amendment as intended.

Schedule 5, entry for Pancrelipase

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 86 of the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2022 (No. 3) (PB 23 of 2022) provides as follows:

[86] Schedule 5, after entry for Ondansetron in the form Wafter 8 mg [GRP-17042]

insert:

Pancrelipase	GRP-26177	Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity	Oral	Panzytrat 25000
Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity (s19A)	Oral	Panzytrat 25 000 (Allergan)

There is no entry for Ondansetron in the form Wafter 8 mg [GRP-17042] in Schedule 5. However, there is an entry for Ondansetron in the form Wafer 8 mg [GRP-17042].

This compilation was editorially changed to insert the entry for Pancrelipase after the entry for Ondansetron in the form Wafer 8 mg [GRP-17042] in Schedule 5 to give effect to the misdescribed amendment as intended.